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SUMMARY 
 
Mitochondrial Ca2+ uptake regulates cellular energetic by triggering ATP synthesis. At the 
same time, Ca2+mit acts as key controller of both cell metabolism and fate. Indeed, a decrease 
in ATP production elicits autophagy induction, while Ca2+ overload causes organelle 
dysfunction and release of caspase cofactors (Glancy and Balaban, 2012; Jouaville et al., 
1999; Rizzuto et al., 2012).  
Several pathological conditions, including tumor formation and progression, are directly 
related to mitochondrial dysfunctions, and reprogramming of mitochondrial metabolism is 
now considered as an emerging hallmark of cancer. Indeed, even in the presence of oxygen, 
cancer cells limit their energy supply largely to glycolysis, leading to the so called “aerobic 
glycolysis” phenotype (Gaude and Frezza, 2014; Hanahan and Weinberg, 2011; Sciacovelli et 
al., 2014). Of note, the dependence on glycolytic fueling is further potentiated by hypoxia, a 
condition that characterizes most tumor microenvironments. Indeed, in response to oxygen 
deprivation, the hypoxia-indicible-factor-1α (HIF-1α) is stabilized and, consequently, 
transcription of glucose transporters and glycolysis-related enzymes is induced (Semenza, 
2010a, b).  In addition, several hereditary tumors have been associated with mutations in 
key mitochondrial enzymes showing that, in specific settings, an altered mitochondrial 
metabolism represents a primary trigger for cancer progression (Gottlieb and Tomlinson, 
2005). 
Consistent with these observations, among the most aggressive human breast tumors, 
triple-negative-breast-cancers (TNBC), a clinically heterogeneous category of breast tumors 
that lack expression of estrogen, progesterone and HER2 receptors, show profound 
metabolic alterations with impaired mitochondrial oxidative metabolism (Elias, 2010; Owens 
et al., 2011). 
6 
 
Our preliminary observations suggested that, in contrast to pre-malignant cells, TNBC 
metastatic cells accumulate high [Ca2+] into the mitochondrial matrix upon agonist 
stimulation. These elevate Ca2+mit transients might be essential for metastatic progression, 
while sensitize premalignant cells to apoptotic stimuli. Accordingly, we hypothesized 
alternative roles of mitochondrial Ca2+, distinct from mitochondrial energy production and 
control of cell death, possibly involved in the metastatic progression of these highly 
malignant breast tumors. 
The molecular characterization of the Mitochondrial Calcium Uniporter (MCU), the highly 
selective channel responsible for Ca2+mit entry into the matrix, opened the chance to 
modulate mitochondrial function by modifying MCU channel’s activity.  
We demonstrated that both pharmacological and genetic inhibition of MCU causes a 
significant decline in TNBC metastatic cell motility and invasiveness. 
Thus, we investigated how Ca2+mit uptake contributes to mitochondrial Reactive-Oxygen-
Species (mROS) production, thus playing a crucial role in the regulation of ROS-dependent 
cascades. Indeed, ROS molecules are considered fundamental molecular effectors for cancer 
progression, by eliciting metabolic adaptations and in vivo metastasis formation (Porporato 
et al., 2014; Tochhawng et al., 2013). Coherently, we observed that antioxidant treatments 
reduce significantly MDA-MB-231 cell migration. Moreover, in the absence of MCU, 
production of mROS is significantly reduced, suggesting that mROS might play a crucial role 
in cell malignancy regulation by Ca2+mit uptake. In addition, MCU silencing inhibits hypoxia-
inducible factor 1α (HIF-1α) transcription, thus impairing the expression of HIF-target genes 
involved in metastasis progression, possibly in a ROS-dependent manner.  Of note, rescue of 
HIF-1α expression restores migration of MCU-silenced TNBC cells. 
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Our results highlight a crucial role of MCU in the control of TNBC metastatic potential and 
indicate that mitochondrial Ca2+ uptake could represent a novel therapeutic target for 
clinical intervention. 
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RIASSUNTO (ITALIANO) 
 
Il flusso di Ca2+ mitocondriale (Ca2+mit) è il principale regolatore della bioenergetica cellulare, 
grazie al fatto che stimola la produzione di ATP. Allo stesso tempo, il Ca2+mit gioca un ruolo 
chiave nella regolazione sia del metabolismo sia della morte cellulare. Infatti, una diminuita 
produzione di ATP porta all’attivazione del processo autofagico (per compensare la 
mancanza di nutrienti) mentre un accumulo elevato di Ca2+ nel mitocondrio porta 
inevitabilmente ad una disfunzione dell’organello, seguita dall’attivazione caspasica e quindi 
dalla morte cellulare (Glancy and Balaban, 2012; Jouaville et al., 1999; Rizzuto et al., 2012). 
Molte patologie, tra cui la formazione e crescita tumorale, sono direttamente correlabili con 
le disfunzioni mitocondriali. Inoltre, il reprogramming del metabolismo mitocondriale è ora 
considerato un aspetto chiave nella patogenesi del cancro. Infatti, anche in presenza di 
ossigeno, le cellule tumorali limitano gran parte del loro supporto energetico alla glicolisi, 
raggiungendo lo stato energetico denominato “glicolisi aerobica” (Gaude and Frezza, 2014; 
Hanahan and Weinberg, 2011; Sciacovelli et al., 2014). Vale la pena evidenziare che la 
dipendenza energetica da un regime glicolitico può venir ulteriormente rafforzata in ipossia, 
condizione che contraddistingue la maggior parte dei microambienti tumorali. Infatti, in 
risposta alla carenza di ossigeno, il fattore trascrizionale HIF-1α viene stabilizzato e, di 
conseguenza, viene indotta la trascrizione di proteine di trasporto del glucosio e di enzimi 
coinvolti direttamente nel metabolismo glicolitico (Semenza, 2010a, b). Inoltre, molti tumori 
ereditari sono stati associati a mutazioni a carico di enzimi mitocondriali, dimostrando in 
questo modo che, in particolari condizioni, un’alterazione  del metabolismo mitocondriale 
può esser considerata fattore eziologico per lo sviluppo del tumore (Gottlieb and Tomlinson, 
2005). 
9 
 
A supporto di queste considerazioni, il tumore mammario metastatico triplo negativo, una 
delle più aggressive ed eterogenee classi di tumori caratterizzata dalla mancata espressione 
dei recettori estrogenici, progestinici ed HER2, mostra una profonda alterazione metabolica 
con ridotta attività ossidativa mitocondriale (Elias, 2010; Owens et al., 2011). 
I nostri risultati preliminari suggeriscono che, al contrario delle cellule pre-maligne, le 
metastatiche triplo negative riescono ad accumulare, dopo stimolazione, alte [Ca2+] 
all’interno della matrice mitocondriale. Transienti di Ca2+mit così elevati possono risultare 
addirittura essenziali per la progressione metastatica, mentre in cellule pre-maligne 
sensibilizzano alla morte cellulare. Di conseguenza, abbiamo ipotizzato ruoli alternativi per il 
Ca2+mit, possibilmente coinvolti nello sviluppo metastatico, che fossero diversi da quelli di 
produzione energetica mitocondriale e di controllo dell’apoptosi. 
La caratterizzazione molecolare dell’Uniporto Mitocondriale del Calcio (dall’inglese MCU), 
canale selettivo per il Ca2+ che ne regola l’ingresso all’interno della matrice, ha aperto la 
possibilità di modulare la funzione mitocondriale modificando l’attività del canale MCU. 
Così, si è deciso di investigare come l’ingresso di Ca2+mit contribuisca alla produzione 
mitocondriale di specie radicaliche dell’ossigeno (ROS), giocando in questo modo un ruolo 
cruciale nella regolazione di tutti i meccanismi di segnale ROS-dipendenti: i ROS sono 
considerati dei critici effettori molecolari della progressione tumorale, promuovendo 
l’adattamento metabolico e la formazione di metastasi in vivo (Porporato et al., 2014; 
Tochhawng et al., 2013). Di conseguenza, si è osservato che trattamenti antiossidanti 
riducono significativamente la migrazione delle cellule tumorali triple negative MDA-MB-
231. Inoltre, è stato verificato che, in assenza di MCU, la produzione di ROS è 
significativamente ridotta, suggerendo così che i ROS mitocondriali giocano un ruolo cruciale 
nella regolazione della malignità tumorale mediata dal Ca2+mit. In aggiunta, è stato 
dimostrato che il silenziamento di MCU inibisce significativamente la trascrizione del fattore 
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di trascrizione HIF-1α, riducendo di conseguenza l’espressione dei geni da lui regolati, 
soprattutto di quelli coinvolti nella progressione metastatica e possibilmente con un 
meccanismo ROS-dipendente. Da notare, a tal proposito, che la ri-espressione di HIF-1α 
ripristina completamente la capacità di migrazione nelle cellule in cui MCU è silenziato. 
In conclusione, i nostri risultati mettono in luce un ruolo cruciale di MCU nel controllo del 
potenziale metastatico del tumore mammario triplo negativo ed indicano che il flusso 
mitocondriale di Ca2+ può rappresentare un nuovo bersaglio terapeutico per un innovativo 
approccio clinico. 
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INTRODUCTION 
CANCER BIOLOGY 
 
Metabolic reprogramming: a hallmark of cancer. 
Cancer is a heterogeneous disease, both biologically and clinically, with distinct histological 
and genetic features. Nevertheless, all tumors are characterized by some biological 
hallmarks among which unrestrained proliferation is the most represented (Hanahan and 
Weinberg, 2011). Several findings indicate that cancer cells undergo a complex metabolic 
reprogramming to satisfy the increased requirement of macromolecules and energy 
necessary for proliferation. The hypothesis that cancer cell metabolism is altered dates back 
to several decades ago. Actually, it was at the beginning of the twentieth century, thanks to 
the emerging biochemistry discoveries, that the energy requirements of cell proliferation 
were initially taken into consideration. The German scientist von Wassermann, an illustrious 
bacteriologist, was the first who hypothesized that cancer cells increase oxygen 
consumption to satisfy their accelerated proliferation rate. Consistent with this hypothesis, 
he started targeting cancer cells using a derivative compound of selenium (selenium–eosin), 
a drug that was thought to disrupt cell respiration (Wassermann, Keysser, & Wassermann, 
1911). Despite very promising trials in rodents, this drug was found to be highly toxic in 
humans, and further investigations revealed that selenium was not as useful in killing cancer 
cells as initially thought, making Wassermann’s observations fruitless (Sugiura & Benedict, 
1929). A more systematic study of cancer metabolism started some years later, thanks to the 
meticulous effort of Otto Warburg. In his early career, he observed that cancer cells 
consume large amounts of glucose through glycolysis even in the presence of oxygen, 
whereas normal cells predominantly use respiration as main energy source (Warburg et al., 
1927). He further hypothesized that cancer transformation was caused by inherent defects 
in mitochondrial function (Warburg, 1956). Despite debated, Warburg’s observations 
12 
 
prompted to understand the biochemical determinants of cancer transformation 
(Weinhouse, 1976). Afterwards, the elucidation of the DNA structure and the discovery of 
oncogenes and tumor-suppressors in cancer, in the late 1970s, temporarily diverted the 
scientific interest to the emerging cancer genetics field.  
Cancer metabolism had been partially neglected until the late 1990s, when the laboratory of 
Chi Van Dang demonstrated that c-Myc oncogene actively contributes to aerobic glycolysis 
by controlling the expression of the glycolytic enzyme lactate dehydrogenase-A (Shim et al., 
1997), revamping the field of cancer metabolism. At this stage, however, altered metabolism 
was seen as nothing more than an epiphenomenon of cell transformation, a by-product of 
the oncogene-induced reprogramming. The link between metabolism and cancer 
progression was further corroborated in the early 2000s, by the discovery that mutations of 
housekeeping metabolic enzymes such as succinate dehydrogenase (SDH) (Baysal et al., 
2000) and fumarate hydratase (FH) (Tomlinson et al., 2002) were associated with hereditary 
forms of cancer. This finding highlighted the possibility that, under some circumstances, 
altered metabolism could be the cause, not the consequence, of cancer transformation 
(Gottlieb and Tomlinson, 2005).  
These observations inspired a renewal of the cancer metabolism field, which combined 
biochemical knowledge on cell metabolism developed in the pre-genomic era, with novel 
high-throughput techniques such as transcriptomics and metabolomics. These 
multidisciplinary efforts culminated with the discovery that a huge number of oncogenes 
and tumor suppressors are implicated in the regulation of cancer cell metabolism (e.g. Ras 
and Akt mutations increase glycolytic flux at different levels (Hsu and Sabatini, 2008)) and 
that key metabolic enzymes, if mutated, predispose to cancer. It is now clear that metabolic 
reprogramming is an obligate step of cancer transformation, required to sustain 
unrestrained proliferation triggered by the activation of oncogenic signalling cascades, which 
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turns tumor metabolism from an anecdotal evidence to a hallmark of cancer (Hanahan and 
Weinberg, 2011).In this chapter, we will discuss aerobic glycolysis, the major component of 
cancer cells metabolic transformation, and how it contributes to cancer growth and 
proliferation. 
 
Aerobic glycolysis 
Non-proliferating cells of differentiated tissues predominantly use mitochondrial oxidative 
phosphorylation (OXPHOS) to fuel their energetic needs. In sharp contrast, in tissue with 
high proliferative rate, as well as in cancer, metabolic pathways shift toward an anabolic 
metabolism, endowed with a high glucose utilization, lactate production and biosynthesis of 
macromolecules (Fig. 1) (Fritz and Fajas, 2010). 
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FIG.1. Schematic differences between oxidative phosphorylation, anaerobic 
glycolysis and aerobic glycolysis  (Vander Heiden et al., 2009) 
 
Aerobic glycolysis is the metabolic process that converts glucose into lactate even under 
aerobic conditions, when normal cells fully oxidize glucose in the mitochondria. Today, 
induction of aerobic glycolysis in tumor cells is called the “Warburg effect” and was initially 
thought to be caused by inherent mitochondrial dysfunction (Warburg, 1956). However, the 
oxidative capacity of mitochondria in cancer cells is intact. We now know that aerobic 
glycolysis is genetically determined (Levine and Puzio-Kuter, 2010) and its role in supporting 
proliferation goes beyond cancer cells. Indeed, aerobic glycolysis has been observed also in 
non-transformed cells, including activated lymphocytes (Wang and Green, 2012) and 
embryonic stem cells (Zhang et al., 2012). These observations indicate that aerobic glycolysis 
can be considered a common metabolic phenotype (metabotype) of proliferating cells. 
However, the reasons why cancer cells switch to aerobic glycolysis are still debated. 
Glycolysis, the process that converts glucose into pyruvate, generates 2 molecules of ATP per 
molecule of glucose, whereas the full oxidation of glucose through mitochondria generates 
31 molecules of ATP. Based on pure stoichiometric calculations, aerobic glycolysis should be 
an inefficient pathway for ATP generation, and the switch to this metabotype seems a 
paradox for cancer cells. However, the current model postulates that the preferential use of 
aerobic glycolysis offers the following advantages to highly proliferative cells. 
First, it focuses cells on the use of glucose, which is the most abundant extracellular nutrient. 
Second, glycolysis is not inefficient at providing cells with ATP, if considering kinetic aspects.  
Actually, although glycolysis generates ATP with lower efficiency than oxidative 
phosphorylation, it produces ATP at a faster rate, when glucose is provided at a sufficiently 
high concentration (Pfeiffer et al., 2001). Furthermore, the glycolytic flux is so efficient in 
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cancer cells compared to non-transformed cells that, by the time one molecule of glucose is 
fully oxidized via respiration, 24 additional ATPs are generated via aerobic glycolysis, 
demonstrating that aerobic glycolysis could still supply 2/3 of the ATP, if respiration fails 
(Koppenol et al., 2011). 
Third, glucose utilization provides essential metabolic intermediates for the biosynthesis of 
diverse macromolecules such as lipids, nucleic acids, non-essential amino acids cysteine, 
glycine, serine and alanine, and for anti-oxidative defenses (Kondoh et al., 2007; Vander 
Heiden et al., 2009). 
 
Given the large amount of glucose taken up by cancer cells in the unit time, it has been 
speculated that the amount of ATP generated by aerobic glycolysis might even exceed the 
ATP requirements of cancer cells. Importantly, without sufficient ATP turnover, ADP and 
phosphate would become a limiting factor for glycolysis, and the accumulation of ATP would 
cause the allosteric inhibition of key metabolic enzymes, such as phosphofructokinase 
(PFK1), blocking the entire glycolytic flux. Therefore, it has been proposed that aerobic 
glycolysis must be coupled to, or even driven by, aberrant ATP-consuming reactions present 
in cancer cells (Racker, 1976).  
A defective Na+/K+ plasma membrane ATPase has been initially proposed to be the major 
sink of ATP in cancer cells (Fagan and Racker, 1978). More recently, other examples of 
cancer-specific ATP-consuming reactions have been reported. The first case entails the 
upregulation of the ER-enzyme ENTPD5, which engages into an ATP-hydrolyzing futile cycle 
resulting in a compensatory increase in aerobic glycolysis (Fang et al., 2010). The second 
example involves the expression of the cancer-specific M2 variant of pyruvate kinase 
(PKM2), which was shown to uncouple pyruvate production from ATP generation, by 
stimulating the transfer of the high-energy phosphate of phosphoenolpyruvate to the 
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glycolytic enzyme phosphoglycerate-mutase (PGAM), instead of ADP (Vander Heiden et al., 
2010). The molecular mechanisms responsible for aerobic glycolysis shift still remain an 
exciting scientific challenge. 
 
FIG.2. Three major components of the metabolic transformation of cancer 
cells are  depicted: aerobic glycolysis, mitochondrial metabolism, and lipid 
synthesis (Sciacovelli et al., 2014). 
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Hypoxia in malignant progression 
Clinical investigations carried out over the last two decades have clearly demonstrated that 
the  prevalence of hypoxic tissue areas [i.e., areas with O2 tensions (pO2 values) ≤2.5 mmHg] 
is a characteristic pathophysiological property of locally advanced solid tumors (Vaupel et al., 
2004). Up to 50–60% of locally advanced solid tumors may exhibit hypoxic and/or anoxic 
tissue areas that are heterogeneously distributed within the tumor mass. Hypoxic/ anoxic 
areas arise as a result of an imbalance between supply and consumption of oxygen. Whereas 
in normal tissues or organs O2 supply matches the metabolic requirements, in solid tumors, 
the O2 consumption rate may exceed the limited O2 supply and result in the development of 
tissue areas with very low [O2]. Cells exposed to hypoxia respond by reducing their overall 
protein synthesis which in turn leads to restrained proliferation and cell cycle 
reprogramming. Hypoxia can hinder or even completely inhibit tumor cell proliferation in 
vitro; the degree of inhibition depends on the severity and duration of hypoxia. Additionally, 
hypoxia can induce programmed cell death (apoptosis) both in normal and in neoplastic cells 
(Vaupel and Harrison, 2004; Vaupel and Mayer, 2007). 
However, sustained hypoxia may also result in a more malignant progression characterized 
by a clinically aggressive phenotype. Depending on the level and (possibly) the duration of 
hypoxia, three processes may be involved in hypoxia-induced tumor progression: alterations 
in gene expression with subsequent changes of the proteome, changes in the genome, and 
clonal selection (Harris, 2002; Semenza, 2000, 2002). Hypoxia-induced proteome and/or 
genome changes leading to cell cycle arrest, differentiation, apoptosis, and necrosis, may 
explain delayed recurrences, dormant micrometastases, and growth retardation which can 
occur in large tumors. This proteome changes promote tumor progression via mechanisms 
enabling cells to overcome nutritive deprivation, to escape from the hostile environment 
and to favor unrestricted growth; tumor quiescent cells that survived under hypoxic 
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conditions may develop an increased potential for local invasive growth and distant 
metastasis, resulting in a poor prognosis (Vaupel and Mayer, 2007). 
A major mechanism mediating these adaptive responses to reduced O2 availability is the 
regulation of transcription by hypoxia-inducible-factor-1 (HIF-1) (Semenza, 2010b). HIF-1 is a 
heterodimeric protein composed of a constitutively expressed HIF-1β subunit and an O2-
regulated HIF-1α subunit.  HIF-1α is subjected to O2-dependent hydroxylation on proline 
residues 402 and 564 by prolyl-hydroxylase-domain-protein-2 (PHD2) and this modification 
creates an interface for interaction with the von Hippel–Lindau tumor suppressor protein 
(VHL), which recruits an E3 ubiquitin-protein ligase that catalyzes polyubiquitination of HIF-
1α, thereby targeting it for proteasomal degradation. 
Under hypoxic conditions, hydroxylation is inhibited, thus HIF-1α rapidly accumulates, 
dimerizes with HIF-1β, and activates transcription of target genes. O2-dependent 
hydroxylation of asparagine-803 by factor inhibiting HIF-1 (FIH-1) impairs the interaction of 
HIF-1α with the transcription co-activators P300 and CBP under normoxic conditions. Both 
PHD2 and FIH-1 use O2 and α-ketoglutarate as substrates and generate CO2 and succinate as 
by-products of the hydroxylation reaction.  
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FIG.3. Molecular mechanism underlying the activation of HIF-1 under hypoxic conditions 
(Harada H., Gene Therapy Strategy for Tumour Hypoxia, 2011). 
 
HIF-2α is a protein with high sequence similarity to HIF-1α. Similarly to HIF-1α, HIF-2α is 
regulated by proline and asparagine hydroxylation, dimerizes with HIF-1β and activates 
transcription of a group of target genes that overlaps with, but is distinct from, those 
regulated by HIF-1α.  
HIF-3α is an inhibitor of HIF-1α that may be involved in feedback regulation as suggested by 
the fact that its expression is transcriptionally regulated by HIF-1α. 
Immunohistochemical analysis of biopsies revealed increased levels of HIF-1α or HIF-2α 
protein (or both) in the majority of primary human cancers and their metastases (compared 
to surrounding normal tissue).  
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HIF-1α can be regulated even under normoxic conditions by a number of oncogenes (i.e. Ras, 
SRC and PI3K) or loss of tumor suppressors such as VHL (von Hippel–Lindau) or PTEN 
phosphatase. Furthermore, increased levels of metabolites i.e. succinate and fumarate (King 
et al.2006), or O2 byproducts like free radicals, can also stabilize HIF-1α (Quintero et al., 
2006). 
The variety of genes that are induced by hypoxia in an HIF-1-dependent manner encode 
proteins that have key roles in every critical aspect of cancer biology (Fig.4), including 
angiogenesis, cell survival, chemotherapy and radiation resistance, immortalization, immune 
evasion, invasion and metastasis, proliferation, glucose metabolism and pH regulation, and 
stem cell maintenance.  
HIF-1α stimulates glycolysis by inducing the expression of glucose transporters GLUTs, which 
are responsible for glucose uptake, and of several enzymes of the glycolytic chain (for 
example hexokinase, phosphofructokinase 1 and aldolase); second, HIF-1α  downregulates 
oxidative phosphorylation, by inducing the expression of pyruvate dehydrogenase kinase 1 
(PDK1), which inhibits the entry of pyruvate into the Krebs cycle by phosphorylation of 
pyruvate dehydrogenase. 
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FIG.4. Selected HIF-1 target genes whose products contribute to cancer 
progression (Semenza, 2009).
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REACTIVE OXYGEN SPECIES 
 
ROS molecules 
Oxygen is an indispensable molecule for the aerobic organisms. However, Reactive Oxygen 
Species (ROS), which are generated by partial O2 reduction, can be formed by a variety of 
mechanisms, including generation during oxidative phosphorylation in the mitochondria, as 
a byproduct of normal cellular aerobic metabolism (Davies, 1995). Indeed, in the aerobic 
environment, mitochondrial ATP generation is coupled to the reduction of molecular oxygen 
to water and to electron transport in the respiratory chain. Reactive oxygen species (ROS) 
are principally formed by complex I and III. Indeed, free electrons responsible for ROS 
generation are released by oxidation of high energy molecules, such as NADH and FAD, and 
carried by “electron carriers” such as Coenzyme Q and Cytochrome C. 
In details, molecular oxygen is found in nature as a diatomic molecule, presenting two 
unpaired electrons with parallel spin in its outermost shell (triplet oxygen) and this 
configuration makes it non reactive and weak oxidant. The complete reduction of one 
molecule of oxygen to 2 molecules of water, at complex IV, requires the transfer of 4 
electrons. However, during electron transfer, some electrons leak out and react with 
environmental O2, leading to an incomplete reduction of molecular O2, thus producing 
reactive intermediates. The products of partial oxygen reduction are the following: 
 Singlet oxygen (1O2): singlet oxygen is commonly formed following exposure to UV or 
visible light in the presence of chromophores that can act as sensitising agents. 
However, it can also be formed by a range of peroxidase enzymes or during the 
reaction of H2O2 with peroxynitrite. 
1O2 interacts with a wide range of biological 
targets, including DNA, RNA, proteins, lipids and sterols (Davies, 2003). 
 Superoxide anion (O2
-): the biological toxicity of superoxide is due to its capacity to 
inactivate iron-sulfur cluster containing enzymes, critical in a wide variety of metabolic 
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pathways, thereby liberating free iron in the cell, which can generate the highly 
reactive hydroxyl radical. In its HO2 form (hydroperoxyl radical) superoxide can also 
initiate lipid peroxidation. Superoxide can also react with nitric oxide (NO) to form 
ONOO-. As such, superoxide is one of the main causes of oxidative stress. Superoxide 
can also produce hydrogen peroxide through a dismutation reaction catalyzed by 
superoxide dismutase.  
 Hydrogen peroxide (H2O2):  it is formed by superoxide anion dismutation. It is lipid 
soluble and thus able to diffuse across membranes. Depending on concentrations, 
H2O2 can act as a signaling molecule. However, it can be a dangerous species for the 
biological systems, as in the presence of ions, such as Fe2+ e Cu+, it can generate 
highly reactive hydroxyl radical.  
 Hydroxyl radical (OH•-): it is the most dangerous reactive oxygen species. The hydroxyl 
radical cannot be eliminated by an enzymatic reaction, as this would require its 
diffusion to the enzyme's active site. As diffusion is slower than the half-life of the 
molecule, it reacts with any oxidizable compound in its vicinity. It can damage virtually 
all types of macromolecules: carbohydrates, nucleic acids (mutations), lipids (lipid 
peroxidation) and amino acids. The only means to protect important cellular structures 
is the use of effective repair systems and antioxidants. 
 
 
ROS induced damage and anti-oxidant defence 
It has been demonstrated that ROS are involved in numerous pathophysiological conditions, 
such as ageing, cancer, myocardial infarct, neurodegenerative diseases and many others 
(Droge, 2002). The effects of oxidative stress on cellular responses including signaling and 
transcription have been attributed to the oxidative modification of macromolecules like 
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proteins, nucleic acids and lipids. Different protein modification have been described that 
include modifications of targets via oxidation of the sulfhydryl (-SH) group of cysteine 
residues, conformational changes due to oxidation-induced intramolecular disulfide bridge 
formation and inter-molecular disulfide bridges leading to protein dimerization. Modification 
of critical cysteine residues of some transcription factors has also been shown to promote 
DNA binding and transactivation, as well as activation, of protein kinases (Thannickal and 
Fanburg, 2000).  Because ROS react with proteins and modify their functions, ROS are likely 
important players in several cellular mechanisms. The initial reaction results in the formation 
of secondary radicals that can diffuse and lead to the propagation of the damage. These 
reactions can terminate only when free radicals are in the presence of molecules able to 
neutralize them (i.e. scavengers) or an enzymatic system, able to metabolize them.  
 
ROS are constantly formed, even under physiological conditions. However, their production 
is counterbalanced by several cellular mechanisms, including enzymatic and non enzymatic 
pathways (Nordberg and Arner, 2001). Among the best characterized enzymatic systems are: 
1. Superoxide dismutase (SOD): in eukaryotic cells, O2
• can be metabolized to hydrogen 
peroxide by two metal-containing SOD isoenzymes, an 80-kDa tetrameric Mn-SOD present in 
mitochondria, and the cytosolic 32-kDa dimeric Cu/Zn-SOD (Weisiger and Fridovich, 1973). In 
the reaction catalyzed by SOD, two molecules of superoxide form hydrogen peroxide and 
molecular oxygen, and are thereby a source of cellular hydrogen peroxide, which is then 
dismutated by catalase. 
2. Catalase (CAT): catalases of many organisms are mainly heme-containing enzymes. This 
enzyme is predominantly localized in mitochondria and peroxisomes, where it catalyzes the 
dismutation of hydrogen peroxide to water and molecular oxygen. One antioxidant role of 
catalase is to lower the risk of hydroxyl radical formation from H2O2 catalyzed by Cu+ or 
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Fe2+ ions. Moreover, catalase binds NADPH, which protects the enzyme from inactivation 
and increases its efficiency. 
3. Glutathione peroxidase (GPx) and glutathione reductase (GR): there are at least four 
different GPx in mammals (GPx1–4), all of them containing selenocysteine (Ursini et al., 
1995). GPx1 and GPx4 (or phospholipid hydroperoxide GPx) are both cytosolic enzymes 
abundant in most tissues. GPx is also localized at the mitochondrial level where it catalyzes 
the reduction of H2O2 produced by Mn-SOD, using glutathione as substrate. This system 
affords protection against low levels of oxidative stress, while catalase is more efficient 
when oxidative burden is increased. In physiological conditions, reduced glutathione (GSH) is 
used for the reduction of H2O2 and is transformed into oxidized glutathione (GSSH). GR is 
the flavoenzyme that restores GSH. 
 
Besides the enzymatic systems, scavengers act as intracellular antioxidants: Vitamin E (N-
tocopherol), Vitamin C (ascorbic acid), Glutathione (GSH), Bilirubin (the end product of heme 
catabolism, can efficiently scavenge peroxyl radical), Uric acid. 
 
ROS signaling in cancer 
In tumorigenic environments, increased generation of ROS often overwhelms the 
antioxidant systems, leading to oxidative stress. Different levels of oxidative stress appear to 
confer different outcomes in cancer cells: while high oxidative stress can lead to cell death 
(Nishikawa, 2008), mild oxidative stress at sub-lethal levels triggers activation of cell 
signaling mechanisms such as increased proliferation, migration and invasion (Porporato et 
al., 2014). 
26 
 
Here we will analyze the main ROS-triggered events involved in cancer progression: cell 
migration, cell adhesion, extra-cellular matrix invasion and epithelial-to-mesenchymal 
transition. 
 
Cell migration. It is a crucial event in embryonic development, cell homeostasis, wound 
healing, and other pathological states such as cancer cell invasion and metastasis (Hurd et 
al., 2012). It encompasses a wide array of cellular changes involving alterations in cell 
structure by formation of protrusions required for migration and regulation of cytoskeleton 
dynamics, expression of adhesion molecules and activation of signaling processes necessary 
for cell migration.  
Members of the Mitogen Activated Protein Kinase (MAPK) family, including extracellular 
signal-regulated kinase (ERK), the c-jun NH-2 terminal kinase (JNK), and the p-38 MAPK are 
activated during cell migration. One mechanism by which ROS mediate activation of these 
pathways is via growth factor stimulation of receptor tyrosine kinases (RTKs) (Wu et al., 
2006). When generated as a result of growth factor receptor stimulation, ROS transmit 
signals to induce cellular changes necessary for migration. Furthermore, in endothelial cells, 
vascular endothelial growth factor (VEGF) has been shown to stimulate ROS production via 
Nox and mitochondrial-dependent pathways (Wang et al., 2011), leading to enhanced cell 
migration. The mechanisms of how activation of growth factor receptors stimulates ROS 
production remain elusive. Important signaling targets of ROS during cell migration include 
the protein kinase C (PKCs) as well as the protein tyrosine phosphatases (PTPs) (Wu, 2006). 
Both PKCs and PTPs contain critical cysteine residues that can be oxidized by ROS. PKC is 
activated upon oxidation while PTP is inhibited. The oxidation states of PKCs and PTPs can 
facilitate RTK signaling by activating the MAPK signaling cascade leading to tumor cell 
migration (Boivin et al., 2010; den Hertog et al., 2008). Interestingly, activated PKC in turn 
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can influence ROS generation, suggesting the existence of a positive feedback mechanism 
from ROS to PKC and vice versa, resulting in signal amplification that enhances cell 
migration.  
 
Cell adhesion. The role of ROS in cell adhesion is well established, since integrin signaling has 
been shown to be accompanied by a mild oxidative burst. Upon activation of integrin 
signaling, ROS are generated from several sources including mitochondria, Nox, and 
lipooxygenases (LOX) (Taddei et al., 2007). Thus, released ROS trigger downstream signaling 
cascades by activating focal adhesion molecules. One of the most well-studied focal 
adhesion proteins is FAK, the principal kinase responsible for the formation of focal adhesion 
complexes (Ben Mahdi et al., 2000). Interactions between FAK and Src kinase have been 
implicated to play crucial roles in cell migration by phosphorylating the focal adaptor 
proteins PKC has been known to be involved in integrin signaling. Moreover, integrin 
signaling activates PKC, which in turn can signal back to activate integrins, suggesting the 
presence of a positive feedback mechanism between integrin and PKCs (Disatnik and Rando, 
1999). Recently, ROS have been identified as an intermediate player in this loop. 
Translocation of PKC to the cell membrane activates integrin signaling that results in 
increased ROS levels. The ROS thus generated oxidize PKC and activate it. Thus, PKC-
dependent integrin signaling generates ROS, which may in turn re-activate PKC, leading to 
sustained ERK activation and enhanced cell migration (Hu et al., 2011). 
 
Cell invasion: Different types of cellular protrusions have been described during cell 
migration, including filopodia, lamellipodia, and invadopodia. Formation of specific 
protrusions is regulated by signalling pathways; for example, Rho activation induces 
filopodia and stress fiber formation, while induction of Rac leads to the formation of 
28 
 
lamellipodia and membrane ruffles (Nobes and Hall, 1999). These cellular protrusions are 
affected by dynamic alterations in the cytoskeleton such as actin cytoskeleton, which in turn 
is controlled by signaling molecules such as Rac. Rac has been identified as an upstream 
regulator of the ROS-producing enzyme Nox, indicating that a pathway exists for ROS-
regulation of the actin cytoskeleton. 
 
Epithelial-to-mesenchymal-transition. EMT encompasses a number of cellular changes that 
permit epithelial cells to attain a mesenchymal phenotype. This is accompanied by loss of 
epithelial markers (including E-cadherin, laminin 1, ZO-1, cytokeratin, and collagen IV), 
induction of mesenchymal markers (such as N-cadherin and vimentin) and upregulation of 
transcription factors (including Snail, Slug, Twist, NF-κB, and Zeb). EMT is accompanied by 
aggressive behavior favoring invasion and metastasis of many cancer types. ROS have been 
widely documented to participate in induction of EMT in cancer, through the activation of 
Snail (Cannito et al., 2008). On the other hand, Snail has also been shown to regulate ROS 
levels, as Snail overexpression in prostate cancer increases intracellular ROS levels (Barnett 
et al., 2011). This suggests a possible feedback mechanism by which ROS and Snail can 
regulate each other and more importantly, both events leading to induction of EMT.  
Expression of genes implicated in hypoxia-induced EMT and angiogenesis may also be 
regulated by ROS. The transcription factor hypoxia inducible factor 1-alpha (HIF-1α) is 
induced by hypoxia and in turn activates downstream transcription of EMT-related genes. 
Interestingly, under hypoxic stress, ROS are produced due to aberrant function of 
mitochondrial complex III (Giannoni et al., 2012), thus stabilizing HIF-1 by oxidative inhibition 
of the HIF-degrading enzyme prolyl hydroxylase. Moreover, under hypoxic conditions, EMT-
related events such as translocation of Snail to the nucleus are found to be determined by 
the amount of intracellular ROS levels (Cannito et al., 2008). 
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Mounting evidence also suggests the influence of TGF-beta induced ROS in EMT-mediated 
cellular changes. As a multi-potent cytokine, TGF-beta plays an important role in EMT and 
tumor progression. Several mechanisms by which TGF-beta induces EMT via regulation of 
intracellular ROS have been proposed. TGF-beta has been shown to increase ROS levels by 
decreasing the expression and activity of the antioxidant protein Glutaredoxin (Grx1) (Lee et 
al., 2010). In mammary epithelial cells expressing oncogenic Ras, downregulation of Grx1 by 
TGF-beta leads to increased intracellular ROS levels promoting EMT. Moreover, increased 
ROS levels downstream of TGF-beta have been shown to activate signaling pathways such as 
MAPK leading to EMT (Felton et al., 2009). 
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MITOCHONDRIA 
 
The general framework 
The mitochondrion represents a unique organelle within the complex endomembrane 
systems that characterize any eukaryotic cell. Beyond the pivotal role they play in ATP 
production, a whole new mitochondrial biology has emerged in the last few decades: 
mitochondria have been shown to participate in many other aspects of cell physiology such 
as amino-acid synthesis, iron-sulphur clusters assembly, lipid metabolism, Ca2+ signaling, 
reactive oxygen species (ROS) production and cell death regulation. 
Hence, many pathological conditions are associated with mitochondria dysfunction, 
including neurodegenerative diseases (Alzheimer’s, Parkinson’s, Hungtinton’s), motoneuron 
disorders (amyotrophic lateral sclerosis, type 2A Charcot-Marie-Tooth neuropathy), 
autosomal dominant optic atrophy, ischemia-reperfusion injury, diabetes, ageing and cancer 
(Duarte et al., 2014; Gaude and Frezza, 2014). 
Understanding how mitochondria can sense and decode various signals from the cytosol and 
other subcellular compartments represents a new exciting challenge in biomedical sciences. 
Mitochondria are defined by two structurally and functionally different membranes: the 
plain outer membrane (OMM), permeable to ions and metabolites up to 5000 Da, and the 
highly selective inner membrane (IMM), characterized by invaginations called cristae which 
enclose the mitochondria matrix. The space between the two membranes is called 
intermembrane space (IMS). The cristae define internal compartments formed by profound 
invaginations originating from narrow tubular structures called cristae junctions (Mannella, 
2006) that limit the diffusion of molecules from the intra-cristae space towards the IMS, thus 
creating a micro-environment where the mitochondrial Electron Transport Chain (mETC) 
complexes are hosted and other proteins are protected from random diffusion. 
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Mitochondrial Ca2+ signaling 
Mitochondria can rapidly accumulate Ca2+ down the electrochemical gradient established by 
the translocation of protons across the inner mitochondrial membrane (IMM), which is 
expressed as a membrane potential difference (∆Ψm) of -180mV (negative inside) under 
physiological conditions (Mitchell, 1966). However, the accurate measurements of [Ca2+] in 
resting cells revealed values well below the affinity of the mitochondrial transporters. Thus, 
the role of mitochondria in Ca2+ homeostasis was considered marginal (i.e. limited to 
conditions of cellular Ca2+ overload), till the development of specific and reliable probes 
directly reported major swings of mitochondrial [Ca2+] even upon physiological stimuli 
(Rizzuto et al., 1992). While enlivening the interest in mitochondrial Ca2+ homeostasis, these 
data raised an apparent contradiction between the prompt accumulation of Ca2+ under 
physiological stimulations and the low affinity of the mitochondrial Ca2+ uniporter, the highly 
selective channel responsible for Ca2+ entry into the mitochondrial matrix, at both resting 
and agonist-stimulated [Ca2+]cyt. 
Based on a large number of experimental proofs, it is now clear that the key of the rapid 
Ca2+mit  accumulation resides in the strategic location of mitochondria in close proximity to 
ER-resident Ca2+ channels and implies the assembly of a dedicated signalling unit at the 
interface of the two organelles.  By labelling mitochondria and ER with targeted spectral 
variants of GFP (mtGFP and erGFP) the presence of overlapping regions of the two 
organelles, called “mitochondria-associated membranes” (MAM) has been revealed and the 
area of the contact sites has been estimated as 5-20% of the total mitochondrial surface 
(Rizzuto et al., 1998). The idea of local Ca2+ microdomains between the mitochondria and 
the ER, was further demonstrated by Rizzuto et al., by fast single-cell imaging of [Ca2+]mit 
with targeted Ca2+-sensitive GFPs (pericams and cameleons), which showed that [Ca2+]mit 
increases originate from a discrete number of ER-sites and then rapidly diffuse through the 
mitochondrial network. 
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Mitochondrial Ca2+ regulation of cellular energetics, cell death and autophagy. 
As mentioned before, mitochondria are the main site of ATP production. When glucose is 
converted to pyruvate by glycolysis, only a small fraction of the available chemical energy 
has been stored in ATP molecules: mitochondria can “release” the remaining amount of 
energy with an outstanding efficiency (from a single glucose molecule, mitochondria 
produce 15 times more ATP than glycolysis). The main enzymatic systems involved in this 
process are the tricarboxylic acid (TCA) cycle and the mETC. Products from glycolysis and 
fatty acid metabolism are converted to acetyl-CoA which enters the TCA cycle where it is 
fully degraded to CO2. More importantly, these enzymatic reactions generate NADH and 
FADH2 which provide reducing equivalents and trigger the electron transport chain. mETC 
consists of five different protein complexes: complex I (NADH dehydrogenase), complex II 
(succinate dehydrogenase), complex III (ubiquinol cytochrome c reductase), complex IV 
(cytochrome c oxidase) and complex V that constitutes the F1F0-ATP synthase. Electrons are 
transferred from NADH and FADH2 through these complexes in a stepwise fashion: as 
electrons move along the respiratory chain, energy is stored as an electrochemical H+ 
gradient across the inner membrane, thus creating a negative mitochondrial membrane 
potential (estimated around -180 mV against the cytosol). H+ are forced to re-enter into the 
matrix mainly  through complex V, which couples this proton driving force to the 
phosphorylation of ADP into ATP, according to the chemiosmotic principle. ATP is then 
released to IMS through the electrogenic   Adenine Nucleotide Translocase (ANT), which 
exchanges ATP with ADP to provide new substrate for ATP synthesis. Finally, ATP can easily 
escape the IMS thanks to the mitochondrial porin of the outer membrane, VDAC (voltage 
dependent anion channel) (Duchen, 2004).  
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A complex Ca2+-sensing machinery, localized in different mitochondrial domains, underlies 
the coupling of aerobic metabolism to Ca2+-mediated signals in the cytosol. In detail, the 
main physiological role of mitochondrial Ca2+ uptake is the control of ATP production rate. 
Indeed, important enzymes of the TCA cycle, i.e. pyruvate-, α-ketoglutarate- and isocitrate-
dehydrogenases (collectively called the Ca2+-sensitive mitochondrial dehydrogenases, 
CSMDHs) are activated by Ca2+, with different mechanisms: the first through a Ca2+-
dependent dephosphorylation step, the others via direct binding to a regulatory site 
(McCormack et al., 1990). Those three enzymes represent rate-limiting steps of the Krebs 
cycle thus controlling the feeding of electrons into the respiratory chain and the generation 
of the proton gradient across the inner membrane, in turn necessary for ATP production.  
Moreover, other Ca2+-dependent mechanisms control mitochondrial metabolism. Indeed, 
metabolite carriers of the inner membrane, such as Aralar1 and Citrin, possess a Ca2+ binding 
site in the portion of the protein protruding in the intermembrane space, which is 
responsible for substrate accumulation into the matrix (Lasorsa et al., 2003).  
 
The growing interest in the molecular processes of Ca2+mit homeostasis further prompted to 
understand increased how programmed cell death (i.e. apoptosis) might be causally linked 
to organelle Ca2+ loading. Indeed, Ca2+ sensitizes cells to apoptotic challenges, acting on the 
mitochondrial checkpoint. Ca2+ binding to Cyclophilin-D positively regulates PTP opening 
(Basso et al., 2005). Once opened, PTP allows the release in the cytosol of intermembrane-
residing apoptotic factors, such as cytochrome C, AIF (apoptosis inducing factor) and 
Smac/DIABLO, which can trigger apoptosis by both a caspase-dependent and a caspase-
independent pathway (Giorgi et al., 2008). Physiological [Ca2+]mit oscillations do not induce 
PTP opening, but become effective with the synergistic action of pro-apoptotic challenges 
(such as ceramide or staurosporin) (Pinton et al., 2001). 
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Another fundamental Ca2+mit-dependent process concerns the control of autophagy. Recent 
reports describe Ca2+ as an inhibitor of autophagy. In 2005, Sakar et al. reported the use of 
Li+ for autophagy stimulation, through inhibition of inositol monophosphatase (IMPases), by 
reducing the IP3 levels (Sarkar et al., 2005). Also chemical inhibition of IP3Rs with 
xestospongin (XeB) or suppression of its expression using siRNA, enhanced autophagy in 
HeLa cells (Criollo et al., 2007). Different downstream mechanisms and effectors have been 
proposed for the inhibitory role of IP3Rs-released Ca2+ in autophagy. In a recent study, 
Cardenas and coworkers showed increased glucose and O2 consumption, as well as PDH and 
AMPK activation in IP3Rs -KO cells, suggesting that constitutive Ca2+ release, through IP3Rs, 
fueling into the mitochondria, increases mitochondrial bio-energetics and ATP production, 
thus suppressing autophagy. When the physiological Ca2+mit uptake is abolished, an increase 
in the AMP/ATP ratio is registered, with a consequent AMPK activation, which stimulates 
autophagy (Cardenas et al., 2010).  
Moreover, cell treatments with ER/SR Ca2+ ATPase (SERCA) inhibitors resulted in increased 
autophagy (Hoyer-Hansen and Jaattela, 2007). 
 
Mitochondrial Ca2+ Uniporter Complex: molecular identity and regulation. 
The fruitful investigation of the molecular identity of the Mitochondrial Calcium Uniporter 
(MCU) took advantage of a genome-wide approach. In 2008, Mootha and co-workers 
reported a mitochondrial “genoteque” called MitoCarta. It was obtained by performing mass 
spectrometry analyses, on both highly purified and crude mitochondrial preparations, from 
14 different mouse tissues, in order to discover genuine mitochondrial proteins, further 
validated by GFP tagging (Pagliarini et al., 2008). By considering only those proteins localized 
in the IMM, expressed in the majority of mammalian tissue and with homologues in 
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vertebrates and kinetoplastids (but not in yeast), they identified a protein named 
“Mitochondrial Calcium Uptake 1” (MICU1). MCU1 possesses one transmembrane domain 
and two canonical EF-hands, essential for Ca2+-sensing. MICU1 was thus recognized as a 
modulator of the Mitochondrial Calcium Uniporter (MCU) (Perocchi et al., 2010).  
The MitoCarta database and the molecular identification of MICU1 set the basis for the 
subsequent identification of MCU. Accordingly, the Mitocarta database was examined with 
unbiased search constraints, on the basis of the phylogenetic appearance of Ruthenium Red-
sensitive Ca2+ uptake (which excluded the yeast proteome, but included the kinetoplastid 
proteome), tissue distribution (which should be ubiquitous in the case of the MCU) and by 
minimal sequence requirements for channels (i.e. the existence of two or more 
transmembrane domains (TMDs)). Finally, our and Mootha’s labs identified a protein, 
encoded by the CCDC109A gene, which satisfies all the requirements of the bona fide 
Mitochondrial Calcium Uniporter (Baughman et al., 2011; De Stefani et al., 2011). MCU 
overexpression in HeLa cells strongly increases Ca2+mit uptake while its silencing by siRNA 
drastically reduces it. Importantly, Baughman et al. demonstrated in vivo that knockdown of 
MCU in liver triggers complete inhibition of Ca2+mit uptake in response to extramitochondrial 
pulses of Ca2+. De Stefani et al. demonstrated that MCU is necessary and sufficient to 
mediate Ca2+ uptake. Indeed, purified MCU formed a RuR-sensitive channel in planar lipid 
bilayers. 
 
In 2012, Mallilankaraman K. and coworkers demonstrated that MICU1 is required to 
preserve basal mitochondrial [Ca2+] levels. Indeed, in its absence mitochondria are 
constitutively loaded with Ca2+, thus triggering excessive reactive oxygen species generation 
and sensitivity to apoptotic stimuli (Mallilankaraman et al., 2012b). Additional publications, 
identified other components of the MCU complex, confirming the hypothesis that MCU is a 
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multisubunit channel, with associated regulators, which partecipate in the tightly regulation 
of the pleiotropic Ca2+mit functions. 
In 2012, Raffello and coworkers characterized a novel protein, named MCUb, with two 
predicted transmembrane domains, 50% sequence similarity with MCU but a different 
expression profile. Based on computational modelling, MCUb includes critical amino-acid 
substitutions in the pore region and therefore MCUb does not form a calcium-permeable 
channel in planar lipid bilayers. In HeLa cells, MCUb is part of the MCU oligomer and exerts a 
dominant-negative effect, reducing the [Ca2+]mit increase evoked by agonist stimulation 
(Raffaello et al., 2013). 
 
Furthermore, Mallilankaraman and coworkers identified a new important component of this 
complex. Indeed, they showed that the MCU-regulator 1 (MCUR1) is an IMM integral 
membrane protein, required for MCU-dependent mitochondrial Ca2+ uptake. Furthermore, 
they showed that this protein is involved in the regulation of oxidative phosphorylation and 
in the activation of AMPK dependent pro-survival autophagy (Mallilankaraman et al., 2012a). 
However, a recent publication of Paupe et al. demonstrated that MCUR1 is a Cytochrome C 
oxidase assembly factor and not a regulator of the Mitochondrial Calcium Uniporter (Paupe 
et al., 2015). 
 
In MICU1-silenced cells, MICU2 is also eliminated and mitochondrial Ca2+ gatekeeping is 
abolished, in agreement with previous reports (Csordas et al., 2013; Mallilankaraman et al., 
2012b). At low [Ca2+], the dominant effect of MICU2 largely shuts down MCU activity; at 
higher [Ca2+], the stimulatory effect of MICU1 allows the prompt response of mitochondria 
to Ca2+ signals generated in the cytoplasm. In 2014, an additional work demonstrated that, 
a protein coded MICU2, is the genuine gatekeeper of MCU (Patron et al., 2014). Indeed, 
37 
 
MICU2 inhibits the channel activity of purified MCU in planar lipid bilayers and, accordingly, 
reduces channel opening at resting [Ca2+], in intact HeLa cells. MICU2 forms an obligate 
heterodimer with MICU1, located in the mitochondrial intermembrane space.  
 
Finally, a 10-kilodalton, metazoan-specific protein, with a single transmembrane domain, has 
been identified. In its absence, uniporter channel activity is lost, despite intact MCU 
expression and oligomerization; thus, the name “Essential MCU Regulator” (EMRE). EMRE 
seems to be required for the interaction of MCU with MICU1 and MICU2. Hence, EMRE 
is essential for uniporter current and regulates the calcium-sensing role of MICU1 and 
MICU2 on MCU conductance (Sancak et al., 2013). 
  
MCU role in cancer progression 
Recently, the role of MCU in cancer has been explored. The molecular characterization of 
the MCU protein complex opened the intriguing chance to modulate mitochondrial function 
by modifying MCU channel’s activity. This possibility could become even more challenging if 
translated into the intricate background cancer pathophysiology, since little is known about 
the contribution of Ca2+mit to tumor progression. 
Prostate and colon cancers overexpress a MCU-targeting microRNA that, by reducing 
mitochondrial Ca2+ uptake, favors cancer cell resistance to apoptotic stimuli, thus increasing 
cell survival (Marchi et al., 2013). Knockdown of MICU1 triggers an increased mROS 
generation thus enhancing the sensitivity of HeLa cells to ceramide-induced cell death 
(Mallilankaraman et al., 2012b). 
In the highly malignant triple negative breast cancer MDA-MB-231 cell model, MCU silencing 
potentiated a caspase-independent cell death triggered by ionomycin, suggesting that MCU 
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overexpression may offer a survival advantage against some apoptotic pathways (Curry et 
al., 2013).  
A recent report pointed out a striking correlation between MCU gene overexpression and 
MICU1 underexpression from breast cancer samples with significantly poorer prognosis 
outcomes. Nonetheless, in the highly aggressive triple negative MDA-MB-231 breast cancer 
cell line, no relevant changes in ROS levels or in cell survival, after both inhibition and 
activation of MCU, were reported (Hall et al., 2014). 
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AIM 
 
Mitochondrial dysfunction is common to many pathological conditions, including cancer. 
Tumor cells frequently exhibit disease-promoting traits linked to alterations in mitochondrial 
function, including increased glycolysis and Reactive Oxygen Species (ROS) production, and 
resistance to apoptotic stimuli.  
Triple Negative Breast Cancer (TNBC), a clinically heterogeneous category of tumors that lack 
expression of estrogen, progesterone and HER2 receptors, show profound metabolic 
alterations with impaired mitochondrial oxidative metabolism (Elias, 2010; Owens et al., 
2011). However, very little is known about mitochondrial Ca2+ regulation or its signaling in 
these tumorigenic settings. 
Metastatic breast cancer cells respond promptly to agonist stimulation, by accumulating 
much higher [Ca2+] into the mitochondrial matrix, compared to premalignant cells. On this 
basis, we hypothesized alternative roles of mitochondrial Ca2+, distinct from those of non-
tumor cells (i.e. mitochondrial energy production and control of cell death) possibly involved 
in the metastatic progression of TNBC. 
We took advantage of the molecular characterization of the Mitochondrial Calcium 
Uniporter (MCU), the highly selective channel responsible for Ca2+ entry into the 
mitochondrial matrix, to investigate whether, by reducing Ca2+mit uptake, metastatic TNBC 
properties, such as cell migration and matrix invasiveness, are affected.  
Then, we focused on mitochondrial Reactive-Oxygen-Species (mROS) production. Indeed, 
mROS molecules are crucial molecular effectors for cancer cell progression, by eliciting both 
metabolic adaptations and in vivo metastasis formation (Porporato et al., 2014; Tochhawng 
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et al., 2013). Accordingly, we aimed at investigating whether Ca2+mit uptake modulates mROS 
production, thus contributing to the regulation of intracellular ROS-dependent pathways.  
Finally, aiming at understanding the molecular effector translating Ca2+-dependent ROS 
signalling into a metastatic phenotype we focused on hypoxia-inducible-factor-1α (HIF-1α), 
the transciption factor responsible for many metastasis-related genes expression. Our study 
highlights an unexpected, intriguing regulation exerted by MCU on HIF-1α. 
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RESULTS 
 
MCU suppression impairs TNBC cell migration. 
In order to decipher the role of mitochondrial Ca2+ signaling in TNBC metastatic potential, we 
took advantage of the MCF10 system of breast cell lines. We first compared the 
mitochondrial Ca2+ uptake responses of premalignant versus malignant cells. Upon agonist 
stimulation, the highly metastatic MCF10CA1a.cl1 transiently accumulated significantly 
higher [Ca2+] than the premalignant MCF10AT1Kcl.2 (Fig. 1a). We hypothesized that high 
Ca2+mit transients, while sensitizing premalignant cells to pro-apoptotic stimuli, may be 
instrumental for metastatic progression.  
 
 
 
 
 
 
 
 
 
FIG.1a. Metastatic cells accumulate higher [Ca2+]mit than premalignant cells 
upon agonist stimulation. Metastatic (MCF10CA1a.cl.1) and premalignant 
(MCF10AT1kcl.2) cell lines were infected with Ad-mitAeqMUT, as Ca2+mit 
indicator. [Ca2+]mit uptake upon ATP stimulation was measured (n= 6, 
***p<0.001). 
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Accordingly, three different metastatic Triple Negative Breast Cancer (TNBC) cell lines were 
analyzed, i.e. BT-549, MDA-MB-468 and MDA-MB-231. In all three models, as expected, 
short interfering RNA (siRNA)-mediated inhibition of the Mitochondrial Calcium Uniporter 
(MCU), the highly selective channel responsible for Ca2+ entry into the mitochondrial matrix, 
caused a significant decline in agonist-induced [Ca2+]mit uptake (Fig.1b-d).  
 
 
 
 
 
 
 
 
 
FIG.1b-d. MCU silencing critically reduces Ca2+mit uptake in TNBC cells. Cells 
were transfected with siMCU or siControl. After 48h, [Ca2+]mit uptake upon ATP 
(Fig.1b, 1d) or Histamine (Fig.1c) stimulation was measured (n=6, ***p< 0.001). 
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Moreover, MCU silencing impaired TNBC cells motility, monitored by wound healing 
migration assay (FIG.1e-g).  
 
 
 
 
 
 
 
 
 
 
 
FIG.1e-g. MCU silencing impairs TNBC cell migration. MDA-MB-468 (Fig.1e), BT-
549 (Fig.1f), MDA-MB-231 (Fig.1g) cells were transfected with siMCU or 
siControl. The day after transfection cells were scratched with a vertically held 
tip (time point 0h). Cell migration into the wounded area was monitored at 48-
hour time point. The recovered area was measured and expressed as a 
percentage relative to 0-hour time point (n=3, ***p<0.001). 
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Importantly, proliferation of BT-549 and MDA-MB-468 cells was unaffected by MCU silencing 
(Fig.1h and 1i). Of note, at 72 hours (which corresponds to the 48-hour time point of the 
wound healing assay) MDA-MB-231 cell growth was modestly but significantly inhibit by 
siMCU (Fig. 1j).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIG.1h-j. MCU depletion does not affect cell proliferation. MDA-MB-468 (Fig.1h), 
BT-549 (Fig.1i), MDA-MB-231 (Fig.1j) cells were transfected with siMCU or 
siControl. Cell number was counted every 24 hours, for 3 days (the 72-hour time 
point corresponds to the 48-hour time point of wound healing assay). Results are 
expressed as ratio R/R0 where R0 is the number of cells at the time of transfection 
(0 hour-time point) (n=3, *p<0.05). 
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MCU silencing blunts cell invasiveness without affecting cell viability, nor reverting the 
mesenchymal phenotype 
In order to further investigate the molecular mechanism involved in the regulation of 
migration by MCU, we selected MDA-MB-231 cells. Of note, re-expression of mMCU rescued 
cell motility in cells in which MCU was silenced, confirming the specificity of siMCU effects 
(Fig.2a).  
 
 
 
FIG.2a. Re-expression of mMCU rescues cell motility of MCU-silenced cells. 
Cells were transfected with siMCU or siControl. Ad-mMCU was used to re-
express MCU (Ad-GFP as control). The day after transduction cells were 
scratched (time point 0h). Cell migration into the wounded area was monitored 
at 48 hour-time point and the recovered area was measured (n=6, ***p<0.001). 
 
Then, we wished to confirm the data on migration obtained by siRNA transfection by a 
pharmacological approach. In agreement with siRNA data, KB-R7943, a specific MCU 
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inhibitor (Santo-Domingo et al., 2007) strongly reduced mitochondrial Ca2+ uptake (Fig.2b) 
and impaired migration (Fig.2c), indicating that both genetic and pharmacological inhibition 
of mitochondrial Ca2+ uptake are effective in controlling cell migration. 
 
 
 
 
 
 
 
 
FIG.2b. Pharmacological inhibition of MCU reduces Ca2+mit uptake of MDA-MB-
231 cells, upon agonist stimulation. Cells were treated for 48 hours with KB-
R7943. Ca2+mit uptake after ATP stimulation was measured (n=6, **p<0.01). 
 
 
 
 
 
 
 
 
 
FIG.2c. Pharmacological inhibition of MCU impairs migration. A cell monolayer 
was scratched (0-hour time point) and treated for 48 hours with KB-R7943. Cell 
migration was monitored at 48-hour time point. (n=6, ***p< 0.001). 
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Next, the invasion potential of TNBC cells upon MCU silencing was investigated. For this 
purpose, an in vitro spheroid formation assay was performed by infecting MDA-MB-231 cells 
with a lentivirus expressing shMCU, demonstrating that 48 hours of MCU silencing deeply 
impairs the ability of TNBC cells to invade the surrounding collagen matrix (Fig.2d). 
Of note, colony formation assay revealed that, in 7 days, cell growth was only partially 
inhibited by shMCU (Fig. 2e). 
 
 
 
 
 
 
 
 
 
FIG.2d. MCU silencing blunts cell invasiveness. Stable shMCU and shControl-
expressing spheroids were plated and let grow into collagen I (0-hour time 
point). The invasion of the surrounding matrix was monitored over time and 
expressed as final invaded area, relative to 0-hour time point (n=6, ***p<0.001). 
FIG.2e. MCU silencing reduces the clonogenic potential of MDA-MB-231 cells. 
Stable shMCU and shControl-expressing cells were plated at low confluence 
(2x103/well of a 6-well plate) and let grow. After 7 days the number of colonies 
was counted (minimum 30 cells/colony, n=6, **p<0.01). 
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As already reported (Curry et al., 2013), we excluded a role of apoptosis and of cell cycle 
arrest in our experimental settings (Fig. 2f-2g). Moreover, the mesenchymal phenotype of 
MDA-MB-231 cells was not reverted to epithelial traits by MCU silencing, as demonstrated 
through the expression profile of the epithelial and mesenchymal markers (Fig.2h).  
 
 
 
FIG.2f. MCU depletion does not induce apoptosis nor necrosis. Cells were 
transfected with siMCU or siControl. 72 hours after transfection cell apoptosis 
and necrosis was measured through FACS analysis, by loading samples with 
Annexin-V and Propidium Iodide (PI). (Q1: PI positive, Q2: PI and Annexin V 
positive, Q3: PI and Annexin V negative, Q4: Annexin V positive. n=4). 
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FIG.2g. MCU depletion does not alter cell cycle. Cells were transfected with 
siMCU or siControl. 72 hours after transfection cell cycle distribution was 
monitored through FACS analysis, by loading samples with Propidium Iodide (PI). 
(P1: G0 phase, P2: G1 phase, P3: S phase, P4: G2-M phase. n=4). 
 
 
 
 
 
 
 
FIG.2h. MCU silencing does not revert the mesenchymal phenotype of MDA-MB-
231 cells. Cells were transfected with siMCU or siControl. The expression profile of 
epithelial (E-Cadherin) and mesenchymal markers (Twist and Vimentin) was 
monitored by western blot. Mouse brain, HeLa and MCF7 cell lysates were used as 
positive controls. 
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MCU downregulation does not compromise mitochondria bioenergetics, although it 
impairs NAD(P)H production. 
The drop in Ca2+mit uptake upon MCU silencing did not alter the mitochondrial membrane 
potential (Fig. 3a), neither affected mitochondrial oxidative phosphorylation capacity, since 
the Oxygen Consumption Rate did not significantly change (Fig. 3b). Nevertheless, we found 
a considerable decline in NAD(P)H production in cells stably expressing shMCU (Fig.3c), thus 
supporting the hypothesis that, although MDA-MB-231 cells are characterized by a 
preferentially glycolytic metabolism, the reduction of Ca2+mit uptake reduces also OXPHOS 
substrate. 
 
 
 
 
 
 
 
 
 
 
FIG.3a. MCU silencing does not compromise mitochondrial membrane 
polarization. Cells were transfected with siMCU or siControl. 48 hours after 
silencing, cells were loaded with tetramethylrhodamine ethyl ester (TMRE) and 
fluorescence was measured (n=3). 
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FIG.3b. MCU depletion does not alter oxygen consumption rate (OCR). Cells 
were transfected with siMCU or siControl. After 72h of MCU silencing oxygen 
consumption rate (OCR) was measured by means of a Seahorse-XF Analyzers. 
Mitochondrial respiration was first inhibited by addition of Oligomycyn (point A), 
then prompted by FCCP (point B) and finally dropped by Rotenone (point C) 
(n=3). 
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FIG.3c. MCU silencing reduces NAD(P)H/NADH ratio. NAD(P)H and NADH 
fuorescence of stable shMCU and shControl-expressing cells was analyzed. 
NAD(P)H/NADH ratio was measured according to the equation that correlates 
NADPH fluorescence decay with NADPH/NADH ratio (Blacker et al., 2014):  
tbound=(tNADPH-tNADH) * ([NADPH]/([NADH]+[NADPH])+tNADH    (n=3, * p<0.05, 
**p<0.01). 
 
 
Mitochondrial ROS production is critically reduced after MCU silencing. 
We next ought to identify the molecular effectors of the migration inhibition mediated by 
MCU silencing. We focused on the role of mitochondrial Reactive Oxygen Species (ROS) since 
they represent signalling molecules that translate mitochondrial inputs into different cell 
responses, including cancer cell migration and invasion (Sena and Chandel, 2012; Tochhawng 
et al., 2013). Antioxidant molecules have been proposed as inhibitors of cell motility, both in 
vitro and in vivo (Porporato et al., 2014). Treatment with two different antioxidants, N-
Acetylcysteine (NAC) and Dithioerythritol (DTE), revealed a dose-dependent impairment on 
migration, measured by wound healing assay (Fig. 4a). In order to specifically analyze the 
role of ROS produced by mitochondria on migration, we thought to validate this finding by 
means of a superoxide scavenging molecule specifically targeted to mitochondria, named 
MitoTEMPO. Migration assays of MitoTEMPO treated cells gave similar results, supporting 
the idea that mitochondrial ROS play a crucial role in TNBC migration (Fig. 4b).  
 
 
 
 
53 
 
 
 
 
 
 
 
 
FIG.4a-b. Antioxidant treatments decreases cell migration. A cell monolayer 
was scratched (0 hour-time point) and treated for 48 hours with N-
Acetylcysteine (NAC) or Dithioerythritol (DTE) (Fig.4a) or with MitoTEMPO 
(Fig.4b). Cell migration into the wounded area was monitored at 48-hour time 
point and the recovered area was measured (n=4, *p<0.05, **p<0.01). 
 
 
Next, we verified the role of mitochondrial Ca2+ uptake on ROS production.  
We took advantage of ectopic expression of mitGRX1-roGFP2, a genetically encoded 
fluorogenic reduction-oxidation-sensitive GFP probe, to specifically measure mitochondrial 
glutathione redox potential (EGSH), as a direct indication of oxidative stress. Live cell imaging 
revealed that MCU silencing caused a marked reduction in GSSG/GSSH ratio (Fig.4c). We 
confirmed this evidence with pHyper-dMito probe, a yellow fluorescent protein (YFP)-based 
biosensor specific for hydrogen peroxide, which showed a reduced mitochondrial H2O2 level 
in siMCU cells. One of the major advantages of these two redox sensitive probes is that they 
are ratiometric by excitation, thus limiting measurement errors deriving from 
photobleaching or concentration variability (Belousov et al., 2006; Gutscher et al., 2008). 
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Furthermore, we supported these results with two different non-ratiometric redox 
indicators, the mitochondrial H2O2-sensitive HyPerRed probe (Ermakova et al., 2014) and the 
red superoxide anion sensitive dye, MitoSOXTM (Fig.4e and 4f). 
All together these results highlight a significant reduction in mitochondrial ROS production 
by MCU silencing, suggesting that ROS may represent the key signaling mediators of MCU-
regulated cell motility 
 
 
 
 
 
 
 
 
 
 
FIG.4c. Mitochondrial GSSG/GSSH ratio is critically reduced after MCU 
silencing. Cells were transfected with siMCU or siControl, together with the 
mitochondrial targeted mitGrx1-Ro-gfp2 probe. 48 hours after transfection the 
glutathione redox potential (EGSH) was measured. H2O2 was added as a positive 
control (n=4, ***p<0.001). 
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FIG.4d-e. Mitochondrial H2O2 levels are critically blunted after MCU depletion. 
Cells were transfected with siMCU or siControl, together with pHyper-dMito 
(Fig.4d) or HyPerRed probe (Fig.4e). 48 hours later H2O2 production was 
measured.  H2O2 was added as a positive control (n=4, **p<0.01, ***p<0.001). 
 
 
 
 
 
 
 
 
 
FIG.4f. Mitochondrial superoxide levels are critically blunted after MCU 
silencing. Cells were transfected with siMCU or siControl. 48 hours later cells 
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were loaded with the red dye MitoSOXTM and superoxide anion levels were 
measured (n=6, *p<0.05). 
 
 
 
MCU silencing alters the activity of Pyruvate Dehydrogenase (PDH) enzyme. 
In agreement with the observation that MCU depletion causes an important drop in 
NAD(P)H production (Fig.3c), we aimed at understanding if any other critical metabolite 
could be affected by MCU silencing. Steady-state Mass Spectrometry (MS) analysis, 
performed by our collaborator Christian Frezza (MRC Cancer Unit - University of Cambridge) 
did not reveal significant changes either in metabolites involved in the TCA cycle activity, or 
in those involved in the glycolytic pathway in MCU-depleted cells, with the exception of a 
small, unexpected, increase in pyruvate level (Fig.5a). 
We further investigated this finding, by measuring PDH phosphorylation level, as an 
indication of its activity. We observed that, after MCU silencing, PDH phosphorylation was 
unaffected (Fig.5b).  
Since PDH is positively regulated by the Ca2+-dependent Pyruvate Dehydrogenase 
Phosphatase  (PDHP), we would have expected an accumulation of phospho-PDH (p-PDH) 
after MCU silencing, as already shown in different physiological models (Pan et al., 2013). 
However, PDH is also subjected to a negative control by the Pyruvate Dehydrogenase Kinase 
(PDK), which in turn is transcriptionally regulated by the hypoxia-inducible-factor-1α (HIF-
1α). HIF-1α is a transcription factor that regulates a wide variety of cancer-related genes, 
involved in metastatic progression. Under normal O2 concentration (i.e. about 20% [O2]) HIF-
1α is rapidly degraded by a mechanism involving the prolyl hydroxylase (PHD) and 
subsequent proteasome recruitment. However, under hypoxic conditions, common of most 
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solid tumors microenvironments, HIF-1α is stabilized. In MDA-MB-231 cells, HIF-1α was 
detected even in normoxic conditions (Fig.6a) and it was significantly accumulated upon O2 
deprivation (i.e. 2% [O2], data not shown). Accordingly, we wanted to verify the effects of 
HIF-1α regulation on PDH enzyme. In order to stabilize HIF-1α and thus emphasize its 
physiological role, we incubated cells overnight in 2% [O2]. Notably, in hypoxic conditions, 
we observed a significant decrease of p-PDH level after MCU depletion (Fig.5b). This data 
suggests a negative effect of MCU silencing on HIF-1α activity that might trigger PDH 
activation. A direct measure of PDH activity after MCU depletion further confirmed this 
result (Fig.5c). 
The reason why MCU silencing potentiates PDH enzyme activity, and thus increase pyruvate 
level, without prompting the mitOXPHOS activity, remains still an unsolved question, in the 
complicate metabolic scenery of this breast cancer model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
FIG.5a. MCU silencing does not compromise TCA or glycolysis-related 
metabolites. Cells were infected with shMCU or shControl and Mass 
Spectrometry (MS) analysis was performed (n=5). 
 
 
 
 
 
 
 
 
FIG.5b. PDH phosphorylation is unaffected after MCU depletion in normoxic 
conditions, while it is decreased under hypoxia. Cells were transfected with 
siMCU or siControl. After 48 hours p-PDH levels were detected by western blot. 
 
 
 
 
 
 
 
 
FIG.5c. MCU silencing enhances PDH activity. Cells were transfected with siMCU 
or siControl. After 48 hours PDH activity was measured (n=4). 
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MCU silencing strongly affects HIF-1α protein level. 
The data reported above suggest that HIF-1α might play an important role in our model and 
deserves further investigation. HIF-1α regulates a large variety of target genes controlling 
the malignancy of several tumor types (Semenza, 2010a).   
We wished to understand whether MCU controls HIF-1α activity in TNBC. MCU silencing 
caused a direct robust downregulation of HIF-1α protein (Fig. 6a). Aiming at understanding 
how siMCU induces HIF-1α depletion, we first investigated the most canonical pathway of 
HIF-1α protein degradation, via PHD activity and proteasome recruitment. We reasoned 
that, if siMCU enhanced HIF-1α protein degradation, proteasome inhibition should lead to 
accumulation of the hydroxylated form OH-HIF-1α (see Introduction, Fig. 2). Thus, we 
treated MDA-MB-231 cells with the proteasome inhibitor MG132 at different time points 
and monitored protein levels of both HIF-1α and OH-HIF-1α. Surprisingly, a significantly 
lower accumulation of OH-HIF-1α occurred in siMCU samples after MG132 treatment, 
compared to cell transfected with control siRNA (Fig.6b), thus suggesting that proteasome-
mediated degradation is not responsible for siMCU-dependent HIF-1α depletion. Hence, an 
alternative mechanism should be involved. In order to confirm this hypothesis we thought to 
separate the effect of siMCU on HIF-1α protein levels from a putative role of MCU on HIF-1α 
transcription. For this purpose we overexpressed a plasmid encoding a HA-tagged, CMV-
promoter driven, HIF-1α (HA- HIF-1α). Again, we inhibited the proteasome activity by 
MG132 treatments. Western blot analysis revealed small differences in HA tag levels 
between siMCU and control samples (Fig.6c), confirming that MCU silencing only partially 
controls HIF-1α protein stability.  
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FIG.6a. HIF-1α levels are reduced after MCU silencing. Cells were transfected 
with siMCU or siControl. After 48 hours HIF-1α protein levels were measured by 
western blot. 
 
 
 
 
 
 
 
 
 
FIG.6b. OH-HIF-1α levels are reduced after MCU silencing. Cells were 
transfected with siMCU or siControl. 48 hours after transfection cells were 
treated with the proteasome inhibitor MG132. OH-HIF-1α protein levels were 
revealed by western blot. 
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FIG.6c. HIF-1α-HA levels are not significantly reduced after MCU silencing. 
Cells were transduced with siMCU or siControl, together with retro-HIF-1α-HA. 
48 hours later cells were treated with MG132 and  HA tag levels were detected 
by western blot. 
 
 
 
A possible alternative mechanism would be that MCU regulates HIF-1α transcription. 
Accordingly, measurements of HIF-1α mRNA levels demonstrated that siMCU strongly 
reduces HIF-1α gene expression, both in normoxic and in hypoxic conditions. Notably, also 
HIF-2 mRNA levels were significantly blunted by siMCU. In addition, selected HIF-target 
genes that, as expected, were upregulated in hypoxia, were also downregulated by siMCU 
(Fig.6d). 
Hence, we aimed at identifying the key effectors triggering siMCU-mediated transcriptional 
downregulation on HIF-1α. We focused on ROS-mediated signalling as regulators of gene 
transcription. As expected, mitochondrial ROS depletion, by MitoTEMPO treatments, 
significantly blunted HIF-1α and HIF-1α -target genes mRNA expression (Fig. 6e).  
Finally we wished to verify whether HIF-1α determines shMCU-mediated effects on cell 
migration. We observed that HIF-1α overexpression (both by wild type and by constitutively 
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active HIF-1α expression plasmids) is able to significantly rescue siMCU-mediated migration 
impairment (Fig.6f) demonstrating that HIF-1α is a crucial downstream effector of siMCU-
induced block of migration. 
 
 
 
 
FIG.6d. MCU silencing significantly reduces mRNA levels of HIF-1α and its 
regulated genes. Cells were transfected with siMCU or siControl. mRNA 
expression of HIF-1α and HIF-1α regulated genes was measured by RealTime-
PCR (n=3, *p<0.05, **p<0.01, ***p<0.001). 
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FIG.6e. Antioxidant treatment reduces mRNA levels of HIF-1α and its 
regulated genes. Cells were treated with MitoTEMPO for 48 hours. mRNA 
expression of HIF-1α and HIF-1α regulated genes was measured by RealTime-
PCR (n=3, *p<0.05). 
 
FIG.6f. HIF-1α overexpression rescues siMCU-mediated migration 
impairment. Cells were transfected with siMCU or siControl. HIF-1α (wt and 
c.a.) were overxpressed by retroviral infection (pBABE as control). The day after 
transduction cells were scratched (time point 0h). Cell migration into the 
wounded area was monitored at 48-hour time point and the recovered area 
was measured (n=3, *p<0.05, ***p<0.001). 
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DISCUSSION AND CONCLUSION 
 
Using a triple negative breast cancer (TNBC) cell model we investigated the contribution of 
the mitochondrial Ca2+ to metastatic progression.  
The molecular characterization of the Mitochondrial Calcium Uniporter (MCU) subunits 
(Baughman et al., 2011; De Stefani et al., 2011) prompted the interest in understanding new 
critical roles of Ca2+mit uptake in the pathophysiology of cancers.  
It is widely recognized that the role of Ca2+ in the mitochondrial matrix goes far beyond the 
general stimulation of cellular energetics. In particular, the role of Ca2+mit accumulation in 
tumor cell survival and response to apoptotic stimuli has been widely investigated (Curry et 
al., 2013; Mallilankaraman et al., 2012b). In addition, in recent times the idea that 
mitochondrial Ca2+ signalling is required for cancer cell progression has been supported by 
the striking correlation between MCU gene overexpression and poor prognosis outcomes, in 
human breast cancer (Hall et al., 2014). At first sight this evidence may appear in contrast 
with the previous finding that a miRNA that specifically targets MCU is expressed in colon 
and prostate primary tumors (Marchi et al., 2013). However, it should be taken into account 
that cancer cells shall adapt and acquire pro-survival mechanisms during their metastatic 
progression, with the aim of developing an unrestrained proliferation. Accordingly, we 
hypothesized that, while in primary tumors low Ca2+mit loading should be preserved in order 
to avoid any apoptotic stimuli sensitization, in metastatic cells, which already escaped death 
and progress to a malignant phenotype, Ca2+mit transients might have different favourable 
roles. To verify this hypothesis, we first focused on two different breast cancer models 
derived from the MCF10 cell system, which allowed us to compare Ca2+mit uptake between 
pre-malignant (MCF10AT1kcl.2) and highly metastatic (MCF10CA1a.cl.1) cell lines. Upon 
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agonist stimulation, metastatic cells transiently accumulated much higher [Ca2+]mit than the 
pre-malignant ones. We thus speculated that elevate Ca2+mit transients might be essential for 
metastatic progression, while being lethal for pre-malignant cells. In order to validate our 
hypothesis we chose three different TNBC metastatic cell lines (BT-549, MDA-MB-231, MDA-
MB-468) and selectively knockdown MCU, thus significantly abolishing Ca2+mit uptake. We 
simultaneously monitored the capacity of those cells to migrate and recover a scratched 
area. Outstandingly, MCU suppression strongly reduced all three TNBC lines migration 
potential, without affecting cell proliferation or death, nor reverting the mesenchymal 
phenotype to epithelial traits. This finding was further supported by pharmacological 
inhibition of the MCU channel activity. For subsequent investigations, MDA-MB-231 cells 
were chosen. First, we verified MCU silencing effects on an additional fundamental 
metastatic feature: the surrounding matrix invasiveness. This competence is a critical 
hallmark of metastatic cells that mimics, in vitro, their potential to spread into distant 
tissues. Notably, MCU stable depletion affected the potential to invade the surrounding 
matrix that, in the long term, is sustained also by an impaired cell proliferation, as revealed 
by the clonogenic assay. 
Our results highlight a new and intriguing role of mitochondrial Ca2+ in the regulation of 
metastatic cell migration and matrix invasiveness, which till now has been completely 
unexplored. The cellular events that underlie this process are still subject to intensive study 
and do not seem to involve mitochondrial membrane depolarization or mitochondrial 
OXPHOS activity suppression. Neverthless, we found a significant reduction in NAD(P)H/NAD 
ratio following MCU silencing, which might be explained by a general slowdown of the TCA 
functionality, considering that Ca2+ ions positively control the activity of three TCA cycle-
related enzymes. On this basis, we considered, as possible consequence of MCU silencing, an 
impaired Reactive Oxygen Species (ROS) production. Indeed, ROS molecules have been 
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commonly  accepted as critical triggers of metastatic progression, both in vitro and in vivo 
(Porporato et al., 2014), in agreement with the observation that, also in our model, 
antioxidant treatments (in particular the one selective for mitochondrial ROS scavenging, i.e. 
MitoTEMPO) result in migration impairment. ROS production was significantly blunted after 
siMCU, as suggested by an accurate oxidative-stress analysis, performed by means of four 
different mitochondria-targeted redox sensitive probes. Thus, the final outcome of MCU 
depletion signal appears to depend on alterations in the redox potential, which could in turn 
involve a large number of intracellular signalling cascades. However, our evidence reveals a 
smaller effect of ROS depletion on migration, compared to MCU knockdown. This 
observation suggests that ROS molecules only partially mediate siMCU effects on the 
metastatic progression, even if they certainly participate to this regulation. Thus, additional 
effectors, which deserve additional investigation, should partecipate to siMCU phenotype. 
In order to further explore these findings, we took advantage of a steady-state MS analysis, 
looking for critical metabolic alterations following Ca2+mit depletion. Unexpectedly, in MCU 
silenced samples no significant changes in TCA cycle or glycolysis-related metabolites 
occured, with the only exception of a small increase in the pyruvate amount. These data, 
together with an enhanced Pyruvate Dehydrogenase Enzyme (PDH) activity, upon MCU 
silencing, left unanswered questions on possible metabolic adaptations arising from Ca2+mit 
reduction, in this complex metastatic model. 
Our results prompted us to consider as final effector of MCU depletion the hypoxia-
inducible-factor-1α (HIF-1α), one of the master regulators of metastasis, which is as well the 
main negative regulator of PDH activity. We obtained evidence of a critical and intriguing 
downregulation of HIF-1α transcription by MCU silencing, resulting from a novel 
proteasome-indipendent regulatory mechanism. The intracellular determinants of HIF-1α 
transcriptional regulation might include ROS as key signalling molecules. 
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On this line, our data demonstrate that ROS scavenging controls HIF-1α (and its regulated 
genes) mRNA expression, although at a lesser extent compared to siMCU.  
Noteworthy, HIF-1α overexpression is completely able to rescue MCU silencing-induced 
migration impairment, suggesting that it represents the key final effector triggering siMCU-
mediated phenotype. 
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MATERIALS AND METHODS 
 
Cell cultures. 
Five different cell lines were used to perform distinct experiments: MDA-MB-231, BT-549, 
MDA-MB-468, MCF10AT1k.cl2 and MCF10CA1a.cl1. 
BT-549 and MDA-MB-468 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (cat# 41966-029 Life technologies), supplemented with 10% Fetal Bovine Serum 
(FBS) (cat# 10500-064, Life technologies). 
MDA-MB-231 cells were cultured in DMEM/F12 medium (1:1) (cat# 31331-028, Life 
technologies), supplemented with 10% FBS (Life technologies). 
MCF10AT1k.cl2 and MCF10CA1a.cl1 cells were cultured in DMEM/F12 freshly supplemented 
with 5% Horse Serum (HS), 10μg/ml Insulin, 20ng/ml EGF, 8.5ng/ml Cholera Toxin, 500ng/ml 
hydrocortisone. 
All media were supplemented with 1% Penicillin G - Streptomycin Sulfate (cat# ECB3001, 
Euroclone) and 1% L-Glutammine (cat# ECB3000D, Euroclone). 
Cells were maintained in culture at 37°C, with 5% CO2. A subcultivation ratio of 1:6 to 1:10 
was guaranteed. 
 
Chemical compound treatments. 
For KB-R7943 treatments (K4144, purchased by Sigma) cells were incubated for 48 hours 
with complete DMEM-10%FBS supplemented with 2 μM of drug (stock 20 mM in DMSO). 
Drug-containing medium must be changed every 24 hours with fresh one. 
For the proteasome inhibitor MG132 treatments (#D00132451, Calbiochem) cells were 
incubated for 15’, 30’ and 1 hour with complete drug-containing medium, at a final 
concentration of 10 μM. 
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Transient transfections , infection and stable transduction. 
Oligonucleotides (10 pmoles/cm2) were transfected using a standard Lipofectamine® 
RNAiMAX Transfection Reagent (cat# 13778-150, Life technologies). To silence MCU a 
specific siRNA was designed: 
siRNA-MCU:  
nucleotides 899–917 of the corresponding mRNA (5’-GCCAGAGACAGACAAUACUtt-3’ and 3’-
ttCGGUCUCUGUCUGUUAUGA-5’). 
Adenovirus expressing mitochondrial mutated aequorin (AdCMVmAqMut) was constructed 
by Rutter et al. from plasmid mtAEQmut (Rizzuto et al., 1992) through the insertion of an 
EcoRI fragment into the multiple cloning site of pcDNA 3 (Invitrogen), and a correctly 
orientated KpnI/XhoI fragment was inserted into vector pAdTrackCMV (Ainscow and Rutter, 
2001). 
The adenovirus expressing MCU-Flag was created (Raffaello et al., 2013) using the AdEasy 
strategy (Stratagene). Mouse MCU was cloned in the pAdTrack-CMV vector (Stratagene) 
using the following primers: 
fw: 5’-GGTACCGCCACCATGGCGGCCGCCGCAGGTAG-3’ 
rv: 5’-CTCGAGTCACTTATCGTCGTCATCCTTGTAATCTTCCTTTTCTCCGATCTGTC-3’ 
The PCR fragment was cloned into KpnI and XhoI sites in pAdTrack-CMV. Subsequent steps 
were performed according to the manufacturer’s instructions (Stratagene). Adenoviral 
vectors contain two distinct promoters that independently drive the expression of the gene 
of interest and of GFP. Therefore, mock plasmid expresses only GFP protein. 
 
To create the constructs for MCU stable knock-down in MDA-MB-231, two interfering 
sequences were selected and cloned into pLKO.1-TRC Cloning vector, according to 
manifacturer's protocol (Addgene): 
shRNA#1: 
71 
 
fw: 5’-CCGGGCAAGGAGTTTCTTTCTCTTTCTCGAGAAAGAGAAAGAAACTCCTTGCTTTTTG-3’ 
rv:5’-AATTCAAAAAGCAAGGAGTTTCTTTCTCTTTCTCGAGAAAGAGAAAGAAACTCCTTGC-3’ 
shRNA#2: 
fw: 5’-CCGGTCAAAGGGCTTAGTGAATATTCTCGAGAATATTCACTAAGCCCTTTGATTTTTG-3’ 
rv: 5’- AATTCAAAAATCAAAGGGCTTAGTGAATATTCTCGAGAATATTCACTAAGCCCTTTGA-3’ 
Each contruct was controlled by sequencing and Western Blotting. We generated lentiviral 
particles from the simultaneous transfection of recombinant shuttle vectors (pCMV8.74 and 
pMD2.VSVG) and the two pLKO.1shRNAs, in packaging HEK293T cells. 
 
HIF-1α overexpression was obtained by transducing MDA-MB-231 cells with retroviral 
vectors (for pCL and pBABE vectors, see plasmids list below). The efficiency of 
overexpression was controlled by Western Blotting.  
For transient ROS-sensitive probes expression, DNA plasmids were transfected using LT1 
reagent (cat# MIR 2300, Mirus). 
 
Plasmids. 
pLPCXmitGrx1-roGFP2 and HyperRed were a gift from I. Bogeski.  
pHyPer-dMito was purchased by Evrogen (#FP942). 
pCMV8.74 and pMD2.VSVG were gently provided by M. Montagner. 
pLKO.1puro-NonTarget shRNA Control was purchased by Sigma (#SHC016V). 
pLKO.1-TRC Cloning Vector (#8453), HA-HIF-1α-wt-pBABE (#19365), HA-HIF-1α-
P402A/P564A (#19005) , pBABE-puro (#1764) and pCL (#12371) were obtained from 
Addgene.  
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Western Blotting and Antibodies. 
To monitor endogenous and overexpressed protein regulation, cells were lysated in RIPA-
buffer (150 mM NaCl, 50 mM Tris, 1 mM EGTA, 1% Triton X-100, 0.1%SDS) and after 30’ of 
incubation on ice, 40 μg of total proteins were loaded according to BCA quantification. 
Proteins were separated by SDS-PAGE electrophoresis, in commercial 4-12% acrylamide gels 
(Life technologies) and transferred onto nitrocellulose membranes (Life technologies) by wet 
electrophoretic transfer. Blots were blocked 1 hr at RT with 5% non-fat dry milk (BioRad) in 
TBS (0.5M Trizma –Sigma, 1.5M NaCl) solution (0.01% Tween) and incubated at 4°C with 
primary antibodies. Secondary antibodies were incubated 1 hr at RT. Washes after antibody 
incubations were done on an orbital shaker, three times for 10’each, with TBS-0,01% tween. 
We used the following antibodies: anti-MCU (1:1000, Sigma #HPA016480), anti-β-tubulin 
(1:7500, Santa Cruz #sc-9104), anti-HA (1:2000, Santa Cruz #sc-7392), anti-HIF1α (1:500, 
Becton Dickinson #610958), anti-hydroxy-HIF1α (1:1000, Cell Signaling #3434), anti-E-
Cadherin (1:1000, Santa Cruz #sc-21791), anti-Vimentin (1:1000, Santa Cruz #sc-5565), anti-
Twist (1:1000, Santa Cruz #sc-15393), anti-phospho-PDH (1:2000, Abcam #ab92696), anti-
PDH (1:1000, Cell Signaling #2784).  
Secondary, HRP-conjugated antibodies (1:5000) were purchased from BioRad. 
 
Aequorin as a Ca2+ indicator. 
Aequorin is a 21 KDa photoprotein isolated from jellyfish Aequorea Victoria which emits blue 
light in the presence of Ca2+. The aequorin originally purified from the jellyfish is a mixture of 
different isoforms called “heterogeneous aequorin” (Shimomura, 1986). In its active form 
the photoprotein includes an apoprotein and a covalently bound prosthetic group, called 
coelenterazine. The apoprotein contains four helix-loop-helix “EF-hand” domains, three of 
which are Ca2+-binding sites. These domains confer to the protein a particular globular 
structure forming the hydrophobic core cavity that accommodates the ligand 
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coelenterazine. When Ca2+ ions bind to the three high affinity EF-hand sites, coelenterazine 
is oxidized to coelenteramide, with a concomitant release of CO2 and emission of light (Head 
et al. 2000). Although this reaction is irreversible, an active aequorin can be obtained in vitro 
by incubating the apoprotein with coelenterazine in the presence of oxygen and 2-
mercaptoethanol. Reconstitution of an active aequorin (expressed recombinantly) can be 
obtained also in living cells by simple addition of coelenterazine into the medium. 
Coelenterazine is highly hydrophobic and has been shown to permeate cell membranes of 
various cell types. Different coelenterazine analogues have been synthetized and are now 
commercially available. 
The possibility of using aequorin as Ca2+ indicator is based on the existence of a well-
characterized relationship between the rate of photon emission and the free [Ca2+].  The first 
method used to correlate the amount of photons emitted to the free [Ca2+] was that 
described by Allen and Blinks (Blinks, 1978). In the following years, this system was improved 
to achieve a simple algorithm that converts luminescence into [Ca2+] values. Under 
physiological conditions of pH, temperature and ionic strength, this relationship is more than 
quadratic in the range of [Ca2+] 10-5-10-7 M.  The presence of 3 Ca2+ binding sites in aequorin 
is responsible for the steep relationship between photon emission rate and free [Ca2+]. The 
[Ca2+] can be calculated from the formula L/Lmax where L is the rate of photon emission at 
any instant during the experiment and Lmax is the maximal rate of photon emission at 
saturating [Ca2+]. The rate of aequorin luminescence is independent of [Ca2+] at very high 
(>10-4 M) and very low [Ca2+]  (< 10-7 M). However, as described below in more details, it is 
possible to expand the range of [Ca2+] that can be monitored with aequorin.  
Although aequorin luminescence is not influenced either by K+ or Mg2+ (which are the most 
abundant cations in the intracellular environment and thus the most likely source of 
interference in physiological experiments) both ions are competitive inhibitors of Ca2+ 
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activated luminescence. 
pH was also shown to affect aequorin luminescence but at values below 7. Due to the 
characteristics described above, experiments with aequorin need to be done in well-
controlled conditions of pH and ionic concentrations, notably of Mg2+. 
 
Recombinant aequorins. 
Aequorin began to be widely used when the cDNA encoding the photoprotein was cloned, 
thus avoiding the purification of the native polypeptide and its microinjection. Moreover, 
the cloning of aequorin gene opened the way to recombinant expression and thus has 
largely expanded the applications of this tool for investigating Ca2+ handling in living cells. In 
particular, recombinant aequorin can be expressed not only in the cytoplasm, but also in 
specific intracellular compartments by including specific targeting sequences in the 
engineered cDNAs (Hartl et al., 1989). Extensive manipulations of the N-terminal of aequorin 
have been shown not to alter the chemiluminescence properties of the photoprotein and its 
Ca2+ affinity. On the other hand, even marginal alterations of the C-terminal either abolish 
luminescence or drastically increase Ca2+ independent photon emission. For these reasons, 
all targeted aequorins synthesized in our laboratory include modifications of the 
photoprotein N-terminal. Three targeting strategies have been adopted: 
1. Inclusion of a minimal targeting signal sequence to the photoprotein cDNA. This strategy 
was initially used to design the mitochondrial aequorin and was followed also to synthesize 
an aequorin localized in the nucleus and in the lumen of the Golgi apparatus. 
2. Fusion of the cDNA encoding aequorin to that of a resident protein of the compartments 
of interest. This approach has been used to engineer aequorins localized in the sarcoplasmic 
reticulum (SR), in the nucleoplasm and cytoplasm (shuttling between the two compartments 
depending on the concentration of steroid hormones), on the cytoplasmic surface of the 
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endoplasmic reticulum (ER) and Golgi and in the subplasmalemma cytoplasmic rim.  
3. Addition to the aequorin cDNA of sequences that code for polypeptides that bind to 
endogenous proteins. This strategy was adopted to localize aequorin in the ER lumen. 
The construct used in our experiments is the mutated isoform of mitochondrial targeted 
aequorin (Brini, 2008): mtAEQmut. It was generated to measure the [Ca2+] of the 
mitochondrial matrix of various cell types. This construct includes the targeting presequence 
of subunit VIII of human cytochrome c oxidase fused to the aequorin cDNA. To expand the 
range of Ca2+ sensitivity that can be monitored the photoprotein was also mutated 
(Asp119>Ala). This point mutation affects specifically the second EF hand motive of wild type 
aequorin. The affinity for Ca2+ of this mutated aequorin (mtAEQmut) is about 20 fold lower 
than that of the wild type. 
 
Luminescence detection. 
The aequorin detection system is derived from that described by Cobbold and Lee (Cobbold 
and Bourne, 1984) and is based on the use of a low noise photomultiplier placed in close 
proximity (2-3  mm) with aequorin expressing cells. Cells are seeded on 13-mm coverslips 
and put into a perfusion chamber. The volume of the chamber is kept to a minimum (about 
200 μl). Cells are continuously perfused via peristaltic pump with KRB saline solution, 
thermostated via a water bath at 37°C.  
The photomultiplier (Hamamatsu H7301) is kept into a dark box. The output of the amplifier- 
discriminator is captured by C8855-01-photoncounting board in an IBM compatible 
microcomputer and stored for further analysis. 
 
Experimental procedures for Ca2+ measurments. 
Cells were seeded onto 13 mm glass coverslips and allowed to grow to 50% confluence. The 
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day before measuring, cells were infected with Adeno-mtAEQmut virus (as previously 
described (Ainscow and Rutter, 2001) together with the indicated siRNA or plasmid. 
The following day, coverslips with cells were incubated with 5 μM coelenterazine for 2 hours 
in KRB saline supplemented with 1mM CaCl2, and then transferred to the perfusion 
chamber. All aequorin measurements were carried out in KRB saline solution. Agonists and 
other drugs were added to the same solution. The agonist stimuli used for maximal 
stimulation were: 100 μM histamine or 100 μM ATP, depending on the cell type. 
The experiments were terminated by lysing cells with 100 μM digitonin in a hypotonic Ca2+-
rich solution (10 mM CaCl2 in H2O), thus discharging the unbound aequorin pool. The light 
signal was collected and calibrated into free [Ca2+] values by an algorithm based on the Ca2+ 
response curve of aequorin at physiological conditions of pH, [Mg2+] and ionic strength, as 
previously described. 
 
Measurement of Mitochondrial Membrane Potential. 
The measurement of mitochondrial membrane potential is based on the distribution of the 
mitochondrion-selective lipofilic cation ”tetramethyl rhodamine methyl ester” dye (TMRM, 
Life Technologies). It is fluorescent and membrane permeable and its distribution into 
intracellular compartments is triggered by electrochemical gradients. Hence, at low 
concentrations, its accumulation into mitochondria was shown to be driven by mitochondrial 
membrane potential (almost -180mV). In order to promote the correct distribution of the 
probe, cells were loaded with the dye-solution at very low concentration (20 nM). Changes 
in mitochondrial membrane potential cause a redistribution of the dye between 
mitochondria and cytoplasmatic environment. Cells were loaded with TMRM stock solution 
(in KRB saline solution) for 20’ at 37°C. The probe was excited at 560 nm and the emission 
light was recorded in the 590-650 nm range. 
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Images were taken every 10 s with a fixed 200 ms exposure time. FCCP (carbonyl cyanide p-
trifluoromethoxyphenylhydrazone, 10 μM), an uncoupler of oxidative phosphorylation, was 
added after 12 acquisitions to completely collapse the electrical gradient established by the 
respiratory chain (∆Ψ). Data are expressed as difference between the TMRM fluorescence 
before and after FCCP depolarization. Confocal laser microscope (Zeiss Axiovert 200, 
objective PlanFluar 40X/1.3) was used in TMRM experiments. 
 
ROS production measurements. 
To determine mitochondrial superoxide levels cells were labeled with 2 mM MitoSOX (Life 
Technologies) for 15‘ at 37°C. MitoSOX™ Red reagent is a novel fluorogenic dye specifically 
targeted to mitochondria in live cells. Oxidation of MitoSOX™ Red reagent by superoxide 
produces red fluorescence, which can be recorded with Absorption/emission maxima at 
~510/580 nm. Maximal ROS production was induced with 10 mM Antimycin-A (Sigma) as a 
positive control.  
In order to measure only mitochondrial Superoxide production and avoid any aspecific 
intracellular accumulation, we performed these measurements microscopically, and 
analyzed images by ImageJ software. 
To determine hydrogen peroxide levels cells were transfected with different probe-
expressing plasmids (HyperRed (Ermakova et al., 2014), pLPCXmitGrx1-roGFP2 and pHyPer-
dMito) together with shMCU plasmid. 
Cells were imaged in Ringer’s buffer solution 48 hours following plasmids transfection, using 
Cell Observer High Speed (Zeiss) microscope equipped with 40x oil Fluar (N.A. 1.3) or 100x oil 
alpha Plan-Fluar (N.A. 1.45) objective, CFP (Semrock HC) and YFP (Zeiss 46HE) singleband 
filters, 420 and 505 nm LED’s (Colibri, Zeiss) and an Evolve 512 EMCCD camera 
(Photometrics). Images were acquired every 5 s for a total of 50 s. Maximal ROS production 
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was induced with 10 mM H2O2 as a positive control. To calculate fluorescence ratios 
background intensity was subtracted and images were corrected for linear crosstalk. pHyPer-
dMito and pLPCXmitGrx1-roGFP2 ratios were calculated by AxioVision software (Zeiss) and 
analyzed in Excel (Microsoft). HyperRed fluorescence was analized by ImageJ software. 
Statistical significance was determined using two-sided unpaired student’s t-test. 
 
Pyruvate Dehydrogenase enzyme activity. 
PDH activity was measured using the PDH enzyme activity microplate assay kit (Abcam 
#ab109902). 
 
Cytofluorimetric Analyses. 
Cytofluorimetric analyses were utilized to analyze cell cycle and cell death induction with the 
use of Annexin V-FITC (Roche) and propidium iodide (Sigma) probes. 
 
Oxygen Consumption Rate Experiments. 
Mitochondrial respiration was followed in a kinetic mode by measuring the oxygen 
consumption rate (OCR) of cell monolayers with XFe Extracellular Flux Analyzer (Seahorse 
Bioscience). 
 
 
Wound healing migration assay. 
For wound healing assays, cells were seeded and transfected at low confluency (30%) in 6-
well plates, in complete medium. After 8 hours, cells were starved in medium without 
serum, for 24 hours. The day after, cell monolayers were scraped with a P200 tip, vertically 
held, to obtain a wound in each well; the medium was replaced with fresh one. Picture of 
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migrating cells were taken at the indicated time point (time 0 as reference). A free software 
tool called “TScratch” (www.chaton.ethz.ch/software) was used for automated images 
analysis. 
 
Clonogenic assay. 
To evaluate clonogenic potential, cells were counted (Scepter™ 2.0 Cell Counter) and seeded 
at very low density (103/well) into 6-well plates. After 7 days colonies were counted. Only 
colonies made of ≥ 30 cells were included in the quantification. 
 
Sheroids formation assay. 
 We put 5*103 cells/well in each well, of a 96-well plate, containing 100 μl Agar 1.5%. The 
plate was left for 72h in the incubator at 37°C. We put 300 μl of Collagen mix solution (L-
Glutamine 1.66mM, FBS 10%, NaHO3 0.213%, Pen/Strep 1%, Collagen 2mg/ml, EMEM) per 
well, in a 24-well plate and waited until it got solid. We harvested spheroids grown into the 
96-well plate with a 200 μl pipette (with cut tips). Spheroids were put in the Collagen mix 
solution and seeded in the 24-well plate containing the Collagen Mix (5 spheroids/400 μl/ 
well). After it got solid, 1 ml /well of complete medium was added. We cultivated cells for 3 
days and took pictures every day. 
Images were analyzed by Fiji ImageJ software, by calculating the area of the spheroid cluster 
(time 0 as reference). 
 
RNA extraction, reverse transcription, and quantitative realtime PCR. 
At least three samples were prepared for each condition. Total RNA was extracted from 
2*106 MDA-MB-231 cells using the SV Total RNA Isolation Kit (Promega) following the 
manufacturer’s instructions. The RNA was quantified with an Eppendorf Bio photometer 
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Plus. From 400 nmol of total RNA of each sample, complementary DNA was generated with 
a cDNA synthesis kit (SuperScript II, Invitrogen) and analysed by real-time PCR using the 
SYBR green chemistry (Bio-Rad). The primers were designed and analysed with Primer3 
(Rozen and Skaletsky, 2000). Real-time PCR standard curves were constructed by using serial 
dilution of cDNAs of the analysed samples, using at least four dilution points and the 
efficiency of all primer sets was between 98 and 102%. The housekeeping genes HPRT-1 and 
GAPDH were used as an internal control for cDNA quantification and normalization of the 
amplified products. Real-time PCR primer sequences were as follows: 
 
HIF-1α: 
FW: TGTACCCTAACTAGCCGAGGAA 
RV: AATCAGCACCAAGCAGGTCATA 
HIF-2α: 
FW: AATGCAGTACCCAGACGGATTT 
RV: ATGTTTGTCATGGCACTGAAGC 
LOX: 
FW: TCAGATTTCTTACCCAGCCGAC 
RV: TTGGCATCAAGCAGGTCATAGT 
PDK1: 
FW: AATGCAAAATCACCAGGACAGC   
RV: ATTACCCAGCGTGACATGAACT   
G6PI: 
FW:  TTACTCCAAGAACCTGGTGACG 
RV:  CTACCAGGATGGGTGTGTTTGA 
 
CA-IX: 
FW: TGGCTGCTGGTGACATCCTA 
RV: TTGGTTCCCCTTCTGTGCTG 
C-MET: 
FW: AGCAATGGGGAGTGTAAAGAGG 
RV: GCACCAAGGAAAATGTGATGCT 
HK2: 
FW: GTGCCCGCCAGAAGACATTA 
RV: TGCTCAGACCTCGCTCCATT 
HPRT-1: 
FW: TGACACTGGCAAAACAATGCA 
RV: GGTCCTTTTCACCAGCAAGCT 
GAPDH: 
FW: GATTCCACCCATGGCAAATTCC 
RV:  CCCCACTTGATTTTGGAGGGAT
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